BCL-6	B-protein
expression	O
during	O
B-cell	O
activation	O
.	O

Translocations	O
involving	O
the	O
BCL-6	B-DNA
gene	I-DNA
are	O
common	O
in	O
the	O
diffuse	O
large	O
cell	O
subtype	O
of	O
non-Hodgkin	O
's	O
lymphoma	O
.	O

Invariably	O
,	O
the	O
BCL-6	B-protein
coding	O
region	O
is	O
intact	O
,	O
but	O
its	O
5	B-DNA
'	I-DNA
untranslated	I-DNA
region	I-DNA
is	O
replaced	O
with	O
sequences	O
from	O
the	O
translocation	B-DNA
partner	I-DNA
.	O

The	O
present	O
study	O
shows	O
that	O
BCL-6	B-protein
expression	O
is	O
regulated	O
in	O
lymphocytes	B-cell_type
during	O
mitogenic	O
stimulation	O
.	O

Resting	B-cell_type
B	I-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
contain	O
high	O
levels	O
of	O
BCL-6	B-RNA
mRNA	I-RNA
.	O

Stimulation	O
of	O
mouse	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
anti-IgM	B-protein
or	I-protein
IgD	I-protein
antibodies	I-protein
,	O
bacterial	O
lipopolysaccharide	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
plus	O
ionomycin	O
,	O
or	O
CD40	B-protein
ligand	I-protein
led	O
to	O
a	O
five-fold	O
to	O
35-fold	O
decrease	O
in	O
BCL-6	B-RNA
mRNA	I-RNA
levels	O
.	O

Similar	O
downregulation	O
of	O
BCL-6	B-RNA
mRNA	I-RNA
was	O
seen	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
stimulated	O
with	O
Staphylococcus	O
aureus	O
plus	O
interleukin-2	B-protein
or	O
anti-IgM	B-protein
antibodies	I-protein
and	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
stimulated	O
with	O
phytohemagglutinin	B-protein
.	O

BCL-6	B-RNA
mRNA	I-RNA
levels	O
began	O
to	O
decrease	O
8	O
to	O
16	O
hours	O
after	O
stimulation	O
,	O
before	O
cells	O
entered	O
S	O
phase	O
.	O

Although	O
polyclonal	O
activation	O
of	O
B	B-cell_type
cells	I-cell_type
in	O
vitro	O
invariably	O
decreased	O
BCL-6	B-protein
MRNA	O
expression	O
,	O
activated	B-cell_type
B	I-cell_type
cells	I-cell_type
from	O
human	O
germinal	O
centers	O
expressed	O
BCL-6	O
mRNA	O
at	O
levels	O
comparable	O
to	O
the	O
levels	O
in	O
resting	O
B	O
cells	O
.	O

Despite	O
these	O
similar	O
mRNA	O
levels	O
,	O
BCL-6	B-protein
protein	O
expression	O
was	O
threefold	O
to	O
34-fold	O
higher	O
in	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
than	O
in	O
resting	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
BCL-6	B-protein
protein	O
levels	O
are	O
controlled	O
by	O
translational	O
or	O
posttranslational	O
mechanisms	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
germinal	O
center	O
reaction	O
provides	O
unique	O
activation	O
signals	O
to	O
B	B-cell_type
cells	I-cell_type
that	O
allow	O
for	O
continued	O
,	O
high-level	O
BCL-6	B-protein
expression	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BCL-6	NULL
Expression	NULL
During	NULL
B-Cell	NULL
Activation	NULL
By	NULL
David	NULL
Allman	NULL
,	NULL
Ashish	NULL
Jain	NULL
,	NULL
Alex	NULL
Dent	NULL
,	NULL
Randal	NULL
R.	NULL
Maile	NULL
,	NULL
Thomas	NULL
Selvaggi	NULL
,	NULL
Marilyn	NULL
R.	NULL
Kehry	NULL
,	NULL
and	NULL
Louis	NULL
M.	NULL
Staudt	NULL
Translocations	NULL
involving	NULL
the	NULL
BCL-6	NULL
gene	NULL
are	NULL
common	NULL
in	NULL
the	NULL
diffuse	NULL
large	NULL
cell	NULL
subtype	NULL
of	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
.	NULL

In-variably	NULL
,	NULL
the	NULL
BCL-6	NULL
coding	NULL
region	NULL
is	NULL
intact	NULL
,	NULL
but	NULL
its	NULL
5	NULL
'	NULL
untranslated	NULL
region	NULL
is	NULL
replaced	NULL
with	NULL
sequences	NULL
from	NULL
the	NULL
translocation	NULL
partner	NULL
.	NULL

The	NULL
present	NULL
study	NULL
shows	NULL
that	NULL
BCL-6	NULL
expression	NULL
is	NULL
regulated	NULL
in	NULL
lymphocytes	NULL
during	NULL
mitogenic	NULL
stimulation	NULL
.	NULL

Resting	NULL
B	NULL
and	NULL
T	NULL
lymphocytes	NULL
contain	NULL
high	NULL
levels	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
.	NULL

Stimulation	NULL
of	NULL
mouse	NULL
B	NULL
cells	NULL
with	NULL
anti-ligM	NULL
or	NULL
IgD	NULL
antibodies	NULL
,	NULL
bacterial	NULL
lipopolysaccharide	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
plus	NULL
ionomycin	NULL
,	NULL
or	NULL
CD40	NULL
ligand	NULL
led	NULL
to	NULL
a	NULL
five-fold	NULL
to	NULL
35-fold	NULL
decrease	NULL
in	NULL
BCL-6	NULL
mRNA	NULL
levels	NULL
.	NULL

Similar	NULL
downregulation	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
was	NULL
seen	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
stimulated	NULL
with	NULL
Staphylococcus	NULL
aureus	NULL
plus	NULL
interleukin-2	NULL
or	NULL
anti-ligM	NULL
antibodies	NULL
and	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
stimulated	NULL
HE	NULL
BCL-6	NULL
GENE	NULL
HAS	NULL
recently	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
etiology	NULL
of	NULL
the	NULL
subset	NULL
of	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
(	NULL
NHL	NULL
)	NULL
with	NULL
a	NULL
large-cell	NULL
component	NULL
.	NULL

'*	NULL
These	NULL
lymphomas	NULL
of	NULL
mature	NULL
B	NULL
lymphocytes	NULL
account	NULL
for	NULL
30	NULL
%	NULL
to	NULL
40	NULL
%	NULL
of	NULL
newly	NULL
diagnosed	NULL
NHL	NULL
cases	NULL
and	NULL
as	NULL
much	NULL
as	NULL
80	NULL
%	NULL
of	NULL
the	NULL
NHL	NULL
mortality	NULL
.	NULL
``	NULL

The	NULL
BCL-6	NULL
gene	NULL
``	NULL
(	NULL
also	NULL
designated	NULL
LAZ3*	NULL
and	NULL
is	NULL
located	NULL
at	NULL
chromosome	NULL
3q27	NULL
,	NULL
a	NULL
common	NULL
site	NULL
of	NULL
translocation	NULL
in	NULL
NHL	NULL
.	NULL

Rearrangements	NULL
of	NULL
the	NULL
BCL-6	NULL
gene	NULL
have	NULL
been	NULL
detected	NULL
in	NULL
as	NULL
many	NULL
as	NULL
45	NULL
%	NULL
of	NULL
diffuse	NULL
large-cell	NULL
lymphomas	NULL
(	NULL
DLCL	NULL
)	NULL
,	NULL
but	NULL
they	NULL
also	NULL
occur	NULL
frequently	NULL
in	NULL
lymphomas	NULL
with	NULL
mixed	NULL
small	NULL
and	NULL
large-cell	NULL
histology	NULL
and	NULL
in	NULL
follicular	NULL
lymphomas	NULL
,	NULL
particularly	NULL
those	NULL
that	NULL
have	NULL
transformed	NULL
into	NULL
more	NULL
clinically	NULL
aggressive	NULL
tumors	NULL
.	NULL

``	NULL
*	NULL
Likewise	NULL
,	NULL
in	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
(	NULL
AIDS	NULL
)	NULL
-associated	NULL
NHL	NULL
,	NULL
BCL-6	NULL
rearrangements	NULL
are	NULL
detectable	NULL
in	NULL
20	NULL
%	NULL
of	NULL
cases	NULL
belonging	NULL
to	NULL
the	NULL
DLCL	NULL
subgroup	NULL
.	NULL
``	NULL

One	NULL
intriguing	NULL
report	NULL
suggested	NULL
that	NULL
BCL-6	NULL
rearrangement	NULL
defines	NULL
a	NULL
biologically	NULL
distinct	NULL
subgroup	NULL
of	NULL
DLCL	NULL
that	NULL
has	NULL
a	NULL
more	NULL
favorable	NULL
prognosis	NULL
after	NULL
chemotherapy	NULL
,	NULL
``	NULL
``	NULL
although	NULL
this	NULL
correlation	NULL
was	NULL
not	NULL
apparent	NULL
in	NULL
all	NULL
studies	NULL
.	NULL
``	NULL

The	NULL
BCL-6	NULL
protein	NULL
has	NULL
six	NULL
Kriippel-like	NULL
zinc	NULL
fingers	NULL
at	NULL
its	NULL
carboxy	NULL
terminus	NULL
and	NULL
thus	NULL
is	NULL
presumably	NULL
involved	NULL
in	NULL
transcriptional	NULL
regulation	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
BCL-6	NULL
belongs	NULL
to	NULL
the	NULL
newly	NULL
recognized	NULL
subfamily	NULL
of	NULL
zinc	NULL
finger	NULL
transcription	NULL
factors	NULL
that	NULL
share	NULL
an	NULL
amino	NULL
terminal	NULL
POZ	NULL
domain	NULL
.	NULL
``	NULL

One	NULL
function	NULL
of	NULL
POZ	NULL
domains	NULL
is	NULL
in	NULL
homodimerization	NULL
and	NULL
hetero-dimerization	NULL
,	NULL
``	NULL
raising	NULL
the	NULL
possibility	NULL
that	NULL
BCL-6	NULL
may	NULL
act	NULL
in	NULL
conjunction	NULL
with	NULL
another	NULL
POZ	NULL
domain	NULL
factor	NULL
.	NULL

Despite	NULL
these	NULL
structural	NULL
clues	NULL
,	NULL
the	NULL
normal	NULL
biologic	NULL
function	NULL
of	NULL
BCL-6	NULL
remains	NULL
to	NULL
be	NULL
elucidated	NULL
.	NULL

One	NULL
consistent	NULL
feature	NULL
of	NULL
the	NULL
BCL-6	NULL
rearrangements	NULL
in	NULL
NHL	NULL
is	NULL
that	NULL
the	NULL
breakpoints	NULL
cluster	NULL
in	NULL
a	NULL
5	NULL
'	NULL
untranslated	NULL
region	NULL
of	NULL
the	NULL
gene	NULL
,	NULL
leaving	NULL
the	NULL
BCL-6	NULL
coding	NULL
region	NULL
intact	NULL
.	NULL

``	NULL
**	NULL
In	NULL
this	NULL
regard	NULL
,	NULL
the	NULL
BCL-6	NULL
rearrangements	NULL
in	NULL
DLCL	NULL
are	NULL
formally	NULL
analogous	NULL
to	NULL
the	NULL
c-myc	NULL
rearrangements	NULL
in	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
.	NULL

This	NULL
observation	NULL
raised	NULL
the	NULL
possibility	NULL
that	NULL
deregulation	NULL
of	NULL
BCL6	NULL
expression	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
malignant	NULL
transformation	NULL
in	NULL
DLCL	NULL
.	NULL

We	NULL
therefore	NULL
surmised	NULL
that	NULL
an	NULL
important	NULL
part	NULL
of	NULL
the	NULL
biology	NULL
of	NULL
BCL-6	NULL
would	NULL
be	NULL
shown	NULL
by	NULL
studying	NULL
the	NULL
control	NULL
of	NULL
its	NULL
expression	NULL
in	NULL
nontransformed	NULL
lymphocytes	NULL
.	NULL

Indeed	NULL
,	NULL
recent	NULL
immunohistochemistry	NULL
studies	NULL
of	NULL
lymphoid	NULL
tissues	NULL
showed	NULL
that	NULL
BCL-6	NULL
protein	NULL
was	NULL
readily	NULL
detectable	NULL
in	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
most	NULL
other	NULL
B	NULL
cells	NULL
in	NULL
human	NULL
Blood	NULL
,	NULL
Vol	NULL
87	NULL
,	NULL
No	NULL
12	NULL
(	NULL
June	NULL
15	NULL
)	NULL
,	NULL
1996	NULL
:	NULL
pp	NULL
5257-5268	NULL
with	NULL
phytohemagglutinin	NULL
.	NULL

BCL-6	NULL
mRNA	NULL
levels	NULL
began	NULL
to	NULL
decrease	NULL
8	NULL
to	NULL
16	NULL
hours	NULL
after	NULL
stimulation	NULL
,	NULL
before	NULL
cells	NULL
entered	NULL
S	NULL
$	NULL
phase	NULL
.	NULL

Although	NULL
polyclonal	NULL
activation	NULL
of	NULL
B	NULL
cells	NULL
in	NULL
vitro	NULL
invariably	NULL
decreased	NULL
BCL-6	NULL
mRNA	NULL
expression	NULL
,	NULL
activated	NULL
B	NULL
cells	NULL
from	NULL
human	NULL
germinal	NULL
centers	NULL
expressed	NULL
BCL-6	NULL
mRNA	NULL
at	NULL
levels	NULL
comparable	NULL
to	NULL
the	NULL
levels	NULL
in	NULL
resting	NULL
B	NULL
cells	NULL
.	NULL

Despite	NULL
these	NULL
similar	NULL
mRNA	NULL
levels	NULL
,	NULL
BCL-6	NULL
protein	NULL
expression	NULL
was	NULL
threefold	NULL
to	NULL
34-fold	NULL
higher	NULL
in	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
than	NULL
in	NULL
resting	NULL
B	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
BCL-6	NULL
protein	NULL
levels	NULL
are	NULL
controlled	NULL
by	NULL
translational	NULL
or	NULL
posttranslational	NULL
mechanisms	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
that	NULL
the	NULL
germinal	NULL
center	NULL
reaction	NULL
provides	NULL
unique	NULL
activation	NULL
signals	NULL
to	NULL
B	NULL
celis	NULL
that	NULL
allow	NULL
for	NULL
continued	NULL
,	NULL
high-level	NULL
BCL-6	NULL
expression	NULL
.	NULL

©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

lymphoid	NULL
tissues	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
In	NULL
the	NULL
present	NULL
report	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
regulation	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
expression	NULL
during	NULL
lymphocyte	NULL
activation	NULL
.	NULL

We	NULL
show	NULL
that	NULL
naive	NULL
B	NULL
lymphocytes	NULL
activated	NULL
by	NULL
a	NULL
variety	NULL
of	NULL
mitogenic	NULL
stimuli	NULL
in	NULL
vitro	NULL
downregulate	NULL
BCL6	NULL
mRNA	NULL
,	NULL
whereas	NULL
activated	NULL
B	NULL
cells	NULL
from	NULL
germinal	NULL
centers	NULL
continue	NULL
to	NULL
express	NULL
BCL-6	NULL
mRNA	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
show	NULL
that	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
express	NULL
dramatically	NULL
more	NULL
BCL6	NULL
protein	NULL
than	NULL
resting	NULL
B	NULL
cells	NULL
,	NULL
despite	NULL
similar	NULL
BCL-6	NULL
mRNA	NULL
levels	NULL
in	NULL
the	NULL
two	NULL
cell	NULL
populations	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
germinal	NULL
center	NULL
microenvironment	NULL
delivers	NULL
unique	NULL
activation	NULL
signals	NULL
to	NULL
B	NULL
lymphocytes	NULL
that	NULL
maintain	NULL
BCL-6	NULL
expression	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Mice	NULL
.	NULL

-	NULL
C57BL/6	NULL
and	NULL
BALB/c	NULL
mice	NULL
were	NULL
purchased	NULL
from	NULL
Jackson	NULL
Laboratories	NULL
(	NULL
Bar	NULL
Harbor	NULL
,	NULL
ME	NULL
)	NULL
.	NULL

Cell	NULL
lines	NULL
.	NULL

HeLa	NULL
,	NULL
K562	NULL
,	NULL
Hut78	NULL
,	NULL
Jurkat	NULL
,	NULL
Nalm6	NULL
,	NULL
Raji	NULL
,	NULL
BJAB	NULL
,	NULL
WIL2-NS	NULL
,	NULL
and	NULL
ARH77	NULL
were	NULL
purchased	NULL
from	NULL
ATCC	NULL
(	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
-immortalized	NULL
B-cell	NULL
line	NULL
VDSO	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
G.	NULL
Tosato	NULL
(	NULL
Food	NULL
and	NULL
Drug	NULL
Administra-tion	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
,	NULL
and	NULL
MBBI1	NULL
was	NULL
cloned	NULL
by	NULL
limiting	NULL
dilution	NULL
of	NULL
the	NULL
EBV-immortalized	NULL
B-cell	NULL
line	NULL
Meade	NULL
,	NULL
which	NULL
was	NULL
provided	NULL
by	NULL
Dr	NULL
T.	NULL
Waldmann	NULL
(	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

The	NULL
B-cell	NULL
line	NULL
RL	NULL
was	NULL
provided	NULL
by	NULL
Dr	NULL
D.	NULL
Longo	NULL
(	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Reagents	NULL
.	NULL

F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
fragments	NULL
of	NULL
goat	NULL
antimouse	NULL
IgM	NULL
antibodies	NULL
and	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
antimouse	NULL
IgM	NULL
were	NULL
pur-	NULL
From	NULL
the	NULL
Metabolism	NULL
Branch	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
and	NULL
the	NULL
Mucosal	NULL
Immunity	NULL
Section	NULL
,	NULL
Laboratory	NULL
of	NULL
Clinical	NULL
Investigation	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
;	NULL
and	NULL
the	NULL
Department	NULL
of	NULL
Immunologi-cal	NULL
Diseases	NULL
,	NULL
Boehringer	NULL
Ingelheim	NULL
Pharmaceuticals	NULL
,	NULL
Inc	NULL
,	NULL
Ridge-field	NULL
,	NULL
CT	NULL
.	NULL

Submitted	NULL
June	NULL
8	NULL
,	NULL
1995	NULL
;	NULL
accepted	NULL
February	NULL
16	NULL
,	NULL
1996	NULL
.	NULL

D.A	NULL
.	NULL

and	NULL
A.J	NULL
.	NULL

made	NULL
equivalent	NULL
contributions	NULL
to	NULL
this	NULL
study	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Louis	NULL
M.	NULL
Staudt	NULL
,	NULL
MD	NULL
,	NULL
PhD	NULL
,	NULL
Metabolism	NULL
Branch	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bldg	NULL
10	NULL
,	NULL
Room	NULL
4N114	NULL
,	NULL
9000	NULL
Rockville	NULL
Pike	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
'advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-4971/96/8712-0035	NULL
$	NULL
3.00/0	NULL
5257	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

5258	NULL
BCL-6	NULL
GAPDH	NULL
[	NULL
¢	NULL
ALLMAN	NULL
ET	NULL
AL	NULL
&	NULL
M	NULL
5	NULL
t	NULL
0	NULL
5	NULL
3	NULL
_	NULL
hO	NULL
__	NULL
ITI	NULL
§	NULL
5	NULL
a	NULL
0	NULL
Egg	NULL
3	NULL
<	NULL
M	NULL
G	NULL
3	NULL
o	NULL
i-	NULL
|P	NULL
#	NULL
#	NULL
c	NULL
,	NULL
-	NULL
#	NULL
=	NULL
7.5	NULL
kb	NULL
4.4	NULL
kb	NULL
«	NULL
8	NULL
&	NULL
8	NULL
=	NULL
&	NULL
e	NULL
``	NULL
-2.4	NULL
kb	NULL
=	NULL
1.4	NULL
kb	NULL
=	NULL
0.2	NULL
kb	NULL
#	NULL
©	NULL
©1480	NULL
e8p	NULL
-	NULL
-~	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
121314151617	NULL
Fig	NULL
1	NULL
.	NULL

BCL-6	NULL
mRNA	NULL
expression	NULL
in	NULL
human	NULL
tissues	NULL
and	NULL
cell	NULL
lines	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Northern	NULL
blot	NULL
analysis	NULL
of	NULL
BCL-6	NULL
and	NULL
GAPDH	NULL
expression	NULL
using	NULL
poly-A*	NULL
RNA	NULL
from	NULL
the	NULL
cervical	NULL
carcinoma	NULL
cell	NULL
line	NULL
HeLa	NULL
;	NULL
the	NULL
erythroleukemia	NULL
cell	NULL
line	NULL
K562	NULL
;	NULL
the	NULL
T-cell	NULL
lines	NULL
Hut78	NULL
and	NULL
Jurkat	NULL
;	NULL
the	NULL
pre-B-cell	NULL
line	NULL
Nalm6	NULL
;	NULL
the	NULL
mature	NULL
B-cell	NULL
lines	NULL
Raji	NULL
,	NULL
BJAB	NULL
,	NULL
MBB1	NULL
,	NULL
VDSO	NULL
,	NULL
WIL2-NS	NULL
,	NULL
and	NULL
ARH77	NULL
;	NULL
and	NULL
the	NULL
indicated	NULL
human	NULL
tissues	NULL
.	NULL

chased	NULL
from	NULL
Jackson	NULL
ImmunoResearch	NULL
(	NULL
West	NULL
Grove	NULL
,	NULL
PA	NULL
)	NULL
.	NULL

F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
;	NULL
goat	NULL
antihuman	NULL
IgM	NULL
was	NULL
purchased	NULL
from	NULL
Southern	NULL
Biotechnology	NULL
Associates	NULL
(	NULL
Birmingham	NULL
,	NULL
AL	NULL
)	NULL
.	NULL

Bacterial	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
;	NULL
Salmonella	NULL
typhosa	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
Fisher	NULL
(	NULL
Malvern	NULL
,	NULL
PA	NULL
)	NULL
.	NULL

Phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
RNase	NULL
H	NULL
,	NULL
and	NULL
propidium	NULL
iodide	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
Chemical	NULL
Co	NULL
(	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

Ionomycin	NULL
and	NULL
Staphylococcus	NULL
aureus	NULL
,	NULL
Cowan	NULL
's	NULL
strain	NULL
(	NULL
SAC	NULL
;	NULL
Pansorbin	NULL
cells	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
Calbiochem	NULL
Corp	NULL
(	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Phytohema-glutinin	NULL
(	NULL
PHA	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
Murex	NULL
Diagnostics	NULL
(	NULL
Bartford	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

Recombinant	NULL
interleukin-2	NULL
(	NULL
rIL-2	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
(	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
.	NULL

Rabbit	NULL
complement	NULL
was	NULL
obtained	NULL
from	NULL
Pel-Freeze	NULL
(	NULL
Rogers	NULL
,	NULL
AR	NULL
)	NULL
.	NULL

The	NULL
anti-Thy	NULL
1.2	NULL
antibody	NULL
,	NULL
J1j	NULL
,	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
M.	NULL
Cancro	NULL
(	NULL
University	NULL
of	NULL
Pennsylvania	NULL
,	NULL
Philadel-phia	NULL
,	NULL
PA	NULL
)	NULL
.	NULL

The	NULL
dextran-coupled	NULL
antimouse	NULL
IgD	NULL
antibody	NULL
,	NULL
H8*/1	NULL
,	NULL
was	NULL
provided	NULL
by	NULL
Dr	NULL
Clifford	NULL
Snapper	NULL
(	NULL
Uniformed	NULL
Health	NULL
Services	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Cloning	NULL
and	NULL
sequencing	NULL
of	NULL
human	NULL
and	NULL
mouse	NULL
BCL-6	NULL
.	NULL

A	NULL
full-length	NULL
human	NULL
BCL-6	NULL
cDNA	NULL
was	NULL
obtained	NULL
by	NULL
screening	NULL
a	NULL
Raji	NULL
cDNA	NULL
library	NULL
with	NULL
a	NULL
BCL-6	NULL
fragment	NULL
isolated	NULL
from	NULL
a	NULL
previously	NULL
described	NULL
subtracted	NULL
library	NULL
.	NULL
``	NULL

''	NULL
The	NULL
full-length	NULL
mouse	NULL
BCL-6	NULL
cDNA	NULL
was	NULL
subsequently	NULL
cloned	NULL
from	NULL
a	NULL
muscle	NULL
cDNA	NULL
library	NULL
(	NULL
Stratagene	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
using	NULL
a	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
-generated	NULL
probe	NULL
spanning	NULL
base	NULL
pairs	NULL
330	NULL
to	NULL
800	NULL
of	NULL
the	NULL
human	NULL
BCL-6	NULL
cDNA	NULL
.	NULL

Automated	NULL
nucleotide	NULL
sequencing	NULL
was	NULL
performed	NULL
with	NULL
an	NULL
Applied	NULL
Biosystems	NULL
373A	NULL
DNA	NULL
sequencer	NULL
(	NULL
Foster	NULL
City	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
mouse	NULL
BCL-6	NULL
mRNA	NULL
sequence	NULL
has	NULL
been	NULL
given	NULL
Genbank	NULL
accession	NULL
no	NULL
.	NULL

U41465	NULL
.	NULL

This	NULL
sequence	NULL
is	NULL
identical	NULL
to	NULL
an	NULL
unpublished	NULL
mouse	NULL
BCL-6	NULL
sequence	NULL
in	NULL
Genbank	NULL
(	NULL
accession	NULL
no	NULL
.	NULL

D38377	NULL
)	NULL
except	NULL
for	NULL
two	NULL
nucleotide	NULL
differences	NULL
in	NULL
the	NULL
coding	NULL
region	NULL
that	NULL
may	NULL
be	NULL
mouse	NULL
strain	NULL
polymorphisms	NULL
.	NULL

One	NULL
nucleotide	NULL
discrepancy	NULL
does	NULL
not	NULL
change	NULL
the	NULL
amino	NULL
acid	NULL
se-quence	NULL
,	NULL
whereas	NULL
the	NULL
second	NULL
changes	NULL
amino	NULL
acid	NULL
456	NULL
from	NULL
glycine	NULL
to	NULL
alanine	NULL
.	NULL

Purification	NULL
of	NULL
mouse	NULL
and	NULL
human	NULL
lymphocytes	NULL
.	NULL

-	NULL
Mouse	NULL
splenic	NULL
B	NULL
cells	NULL
from	NULL
8-	NULL
to	NULL
12-week-old	NULL
mice	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
'	NULL

''	NULL
Human	NULL
naive	NULL
B	NULL
cells	NULL
were	NULL
purified	NULL
by	NULL
positive	NULL
selection	NULL
from	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
with	NULL
anti-CD19-coated	NULL
magnetic	NULL
beads	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL
``	NULL

The	NULL
resulting	NULL
B-cell	NULL
populations	NULL
were	NULL
routinely	NULL
95	NULL
%	NULL
surface	NULL
Ig	NULL
M*	NULL
as	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Germinal	NULL
center	NULL
B	NULL
cells	NULL
were	NULL
purified	NULL
as	NULL
described	NULL
``	NULL
from	NULL
human	NULL
tonsils	NULL
obtained	NULL
from	NULL
Holy	NULL
Cross	NULL
Hospital	NULL
(	NULL
Silver	NULL
Spring	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
were	NULL
greater	NULL
than	NULL
95	NULL
%	NULL
CD38	NULL
,	NULL
CD20*IgD~	NULL
.	NULL

Human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
were	NULL
isolated	NULL
as	NULL
described	NULL
``	NULL
and	NULL
were	NULL
70	NULL
%	NULL
to	NULL
95	NULL
%	NULL
CD2*	NULL
CDS*	NULL
after	NULL
enrichment	NULL
.	NULL

Cell	NULL
cultures	NULL
.	NULL

Bulk	NULL
cultures	NULL
``	NULL
and	NULL
proliferation	NULL
assays'*	NULL
with	NULL
mouse	NULL
splenic	NULL
B	NULL
cells	NULL
were	NULL
set	NULL
up	NULL
as	NULL
described	NULL
.	NULL

Purified	NULL
human	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
at	NULL
2	NULL
X	NULL
10°	NULL
cells/mL	NULL
in	NULL
RPMI	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
,	NULL
1	NULL
ug/ml	NULL
glutamine	NULL
,	NULL
1	NULL
pg/mL	NULL
each	NULL
of	NULL
penicillin	NULL
and	NULL
streptomycin	NULL
,	NULL
and	NULL
5	NULL
x	NULL
10~5	NULL
mol/L	NULL
2-mercaptoethanol	NULL
.	NULL

Unless	NULL
indicated	NULL
otherwise	NULL
,	NULL
cultures	NULL
were	NULL
preincubated	NULL
at	NULL
37°C	NULL
for	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BCL-6	NULL
EXPRESSION	NULL
DURING	NULL
B-CELL	NULL
ACTIVATION	NULL
Akata	NULL
+	NULL
Anti-lg	NULL
Akata	NULL
LCL-2	NULL
LCL-4	NULL
BCL-6	NULL
-	NULL
aw	NULL
»	NULL
«	NULL
$	NULL
#	NULL
#	NULL
#	NULL
1	NULL
2	NULL
3	NULL
4	NULL
Fig	NULL
1	NULL
.	NULL

(	NULL
cont	NULL
'd	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Northern	NULL
blot	NULL
analysis	NULL
of	NULL
BCL-6	NULL
and	NULL
GAPDH	NULL
expression	NULL
using	NULL
total	NULL
RNA	NULL
from	NULL
the	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
line	NULL
,	NULL
Akata	NULL
,	NULL
with	NULL
and	NULL
without	NULL
stimulation	NULL
with	NULL
anti-lg	NULL
antibodies	NULL
for	NULL
24	NULL
hours	NULL
and	NULL
from	NULL
two	NULL
EBV-transformed	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
,	NULL
LCL-2	NULL
and	NULL
LCL-4	NULL
.	NULL

GAPDH	NULL
1	NULL
hour	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
indicated	NULL
stimulus	NULL
.	NULL

Mouse	NULL
splenic	NULL
B	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
50	NULL
Lg/mL	NULL
anti-Ig	NULL
M	NULL
,	NULL
50	NULL
pg/mL	NULL
LPS	NULL
,	NULL
10	NULL
ng/mL	NULL
anti-IgD	NULL
dextran	NULL
,	NULL
or	NULL
1	NULL
ng/mL	NULL
PMA	NULL
plus	NULL
1	NULL
g/mL	NULL
ionomycin	NULL
.	NULL

Human	NULL
B	NULL
cells	NULL
and	NULL
the	NULL
AKATA	NULL
B-cell	NULL
line	NULL
were	NULL
stimulated	NULL
with	NULL
50	NULL
ug/mL	NULL
anti-IgM	NULL
or	NULL
1:20,000	NULL
wt/vol	NULL
SAC	NULL
plus	NULL
5	NULL
ng/mL	NULL
rIL-2	NULL
,	NULL
and	NULL
human	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
1	NULL
pg/mL	NULL
PHA	NULL
.	NULL

Before	NULL
RNA	NULL
isolation	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
cold	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
and	NULL
checked	NULL
for	NULL
viability	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

DNA	NULL
content	NULL
was	NULL
determined	NULL
by	NULL
staining	NULL
cell	NULL
aliquots	NULL
with	NULL
propidium	NULL
iodide	NULL
by	NULL
standard	NULL
methods	NULL
,	NULL
``	NULL
followed	NULL
by	NULL
analysis	NULL
on	NULL
a	NULL
Becton	NULL
Dickinson	NULL
FACscan	NULL
with	NULL
CellQuest	NULL
software	NULL
.	NULL

CD40	NULL
ligand	NULL
stimulation	NULL
of	NULL
B	NULL
cells	NULL
.	NULL

CD40	NULL
ligand	NULL
was	NULL
expressed	NULL
in	NULL
insect	NULL
cells	NULL
using	NULL
a	NULL
recombinant	NULL
baculovirus	NULL
encoding	NULL
full-length	NULL
human	NULL
CD40	NULL
ligand	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
K.	NULL
Meek	NULL
and	NULL
P.	NULL
Lipsky*	NULL
)	NULL
.	NULL

High-titer	NULL
virus	NULL
stocks	NULL
grown	NULL
in	NULL
Sf9	NULL
cells	NULL
or	NULL
Sf21	NULL
cells	NULL
using	NULL
standard	NULL
techniques*	NULL
were	NULL
used	NULL
to	NULL
infect	NULL
Sf9	NULL
cells	NULL
grown	NULL
in	NULL
suspension	NULL
cul-	NULL
5259	NULL
ture	NULL
for	NULL
66	NULL
hours	NULL
at	NULL
27°C	NULL
(	NULL
multiplicity	NULL
of	NULL
infection	NULL
[	NULL
MOI	NULL
]	NULL
of	NULL
20	NULL
)	NULL
.	NULL

Infected	NULL
Sf9	NULL
cells	NULL
were	NULL
harvested	NULL
by	NULL
centrifugation	NULL
,	NULL
washed	NULL
twice	NULL
with	NULL
ice-cold	NULL
Rinaldini	NULL
's	NULL
salt	NULL
solution	NULL
(	NULL
Sigma	NULL
)	NULL
containing	NULL
1.0	NULL
mmol/	NULL
L	NULL
CaCl1	NULL
;	NULL
,	NULL
and	NULL
membranes	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
.	NULL

**	NULL
``	NULL
``	NULL
Membranes	NULL
were	NULL
washed	NULL
,	NULL
resuspended	NULL
in	NULL
Dulbecco	NULL
's	NULL
PBS	NULL
,	NULL
and	NULL
titrated	NULL
in	NULL
a	NULL
B-cell	NULL
proliferation	NULL
assay	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
The	NULL
optimal	NULL
dilution	NULL
of	NULL
CD40	NULL
ligand-containing	NULL
membranes	NULL
was	NULL
then	NULL
used	NULL
to	NULL
stimulate	NULL
3	NULL
X	NULL
10	NULL
``	NULL
purified	NULL
mouse	NULL
splenic	NULL
B	NULL
cells	NULL
in	NULL
a	NULL
10-mL	NULL
bulk	NULL
culture	NULL
.	NULL

Preparation	NULL
of	NULL
RNA	NULL
and	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL

-	NULL
Total	NULL
RNA	NULL
was	NULL
prepared	NULL
with	NULL
the	NULL
Stratagene	NULL
RNA	NULL
isolation	NULL
kit	NULL
(	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
poly-A*	NULL
RNA	NULL
was	NULL
isolated	NULL
by	NULL
selection	NULL
on	NULL
oligo-dT	NULL
cellulose	NULL
(	NULL
Col-laborative	NULL
Biomedical	NULL
Products	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Poly-A*	NULL
RNA	NULL
from	NULL
human	NULL
tissues	NULL
was	NULL
purchased	NULL
from	NULL
Clontech	NULL
(	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
standard	NULL
methods	NULL
.	NULL
``	NULL

''	NULL
Mouse	NULL
RNA	NULL
blots	NULL
were	NULL
hybridized	NULL
with	NULL
a	NULL
1,200-bp	NULL
EcoRI	NULL
fragment	NULL
derived	NULL
from	NULL
the	NULL
mouse	NULL
BCL-6	NULL
cDNA	NULL
,	NULL
stripped	NULL
,	NULL
and	NULL
then	NULL
rehybridized	NULL
with	NULL
a	NULL
800-bp	NULL
Pst	NULL
I	NULL
fragment	NULL
derived	NULL
from	NULL
rat	NULL
GAPDH	NULL
.	NULL
``	NULL

Human	NULL
RNA	NULL
blots	NULL
were	NULL
hybridized	NULL
with	NULL
the	NULL
human	NULL
BCL-6	NULL
PCR	NULL
fragment	NULL
described	NULL
above	NULL
,	NULL
stripped	NULL
,	NULL
and	NULL
then	NULL
rehybridized	NULL
with	NULL
a	NULL
human	NULL
GAPDH	NULL
PCR	NULL
fragment	NULL
.	NULL

Quantitation	NULL
of	NULL
Northern	NULL
blots	NULL
was	NULL
achieved	NULL
on	NULL
a	NULL
phosphorimager	NULL
or	NULL
densitometer	NULL
,	NULL
each	NULL
equipped	NULL
with	NULL
ImageQuant	NULL
software	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
,	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
.	NULL

Two	NULL
different	NULL
rabbit	NULL
polyclonal	NULL
anti-BCL-6	NULL
antibodies	NULL
were	NULL
used	NULL
for	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

Antipeptide	NULL
antisera	NULL
(	NULL
Research	NULL
Genetics	NULL
,	NULL
Huntsville	NULL
,	NULL
AL	NULL
)	NULL
were	NULL
prepared	NULL
by	NULL
immunizing	NULL
rabbits	NULL
with	NULL
the	NULL
peptide	NULL
C-amino	NULL
caproic	NULL
acid-EDEIALH-FEPPNAPLNRK	NULL
(	NULL
derived	NULL
from	NULL
BCL-6	NULL
amino	NULL
acids	NULL
310	NULL
through	NULL
327	NULL
)	NULL
coupled	NULL
to	NULL
keyhole	NULL
limpet	NULL
hemocyanin	NULL
.	NULL

Affinity-purified	NULL
anti-BCL-6	NULL
antibodies	NULL
were	NULL
generated	NULL
from	NULL
the	NULL
antisera	NULL
using	NULL
an	NULL
affinity	NULL
column	NULL
prepared	NULL
from	NULL
the	NULL
immunogen	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
an	NULL
anti-	NULL
antisera	NULL
generated	NULL
against	NULL
BCL-6	NULL
amino	NULL
acids	NULL
3	NULL
through	NULL
484	NULL
was	NULL
used	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

For	NULL
Western	NULL
blot	NULL
analysis	NULL
,	NULL
2.5	NULL
x	NULL
10°	NULL
germinal	NULL
center	NULL
or	NULL
human	NULL
peripheral	NULL
blood	NULL
B	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
PBS	NULL
,	NULL
lysed	NULL
with	NULL
the	NULL
addition	NULL
of	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
2	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacryl-amide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
SDS-PAGE	NULL
)	NULL
sample	NULL
buffer	NULL
containing	NULL
2-mercaptoethanol	NULL
,	NULL
``	NULL
°	NULL
boiled	NULL
for	NULL
5	NULL
minutes	NULL
,	NULL
and	NULL
briefly	NULL
sonicated	NULL
.	NULL

Samples	NULL
were	NULL
electrophoresed	NULL
through	NULL
a	NULL
7.5	NULL
%	NULL
SDS-PAGE	NULL
gel	NULL
,	NULL
and	NULL
proteins	NULL
were	NULL
transferred	NULL
to	NULL
a	NULL
nitrocellulose	NULL
membrane	NULL
(	NULL
BA-S	NULL
NC	NULL
;	NULL
Schleicher	NULL
&	NULL
Schuell	NULL
,	NULL
Keene	NULL
,	NULL
NH	NULL
)	NULL
using	NULL
a	NULL
Mini-Transblot	NULL
apparatus	NULL
(	NULL
Biorad	NULL
,	NULL
Hercules	NULL
,	NULL
CA	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
.	NULL

Blots	NULL
were	NULL
incubated	NULL
with	NULL
anti-BCL-6	NULL
antibodies	NULL
at	NULL
3.3	NULL
ug/mL	NULL
in	NULL
blocking	NULL
solution	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
room	NULL
(	NULL
PBS	NULL
with	NULL
5	NULL
%	NULL
wt/vol	NULL
nonfat	NULL
dry	NULL
milk	NULL
)	NULL
.	NULL

Bound	NULL
antibody	NULL
was	NULL
detected	NULL
either	NULL
using	NULL
an	NULL
ECL	NULL
kit	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
or	NULL
by	NULL
incubating	NULL
the	NULL
blot	NULL
with	NULL
'*I-labeled	NULL
donkey	NULL
antirabbit	NULL
antibodies	NULL
(	NULL
1	NULL
in	NULL
blocking	NULL
solution	NULL
;	NULL
Amersham	NULL
)	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
stripped	NULL
of	NULL
bound	NULL
antibody	NULL
by	NULL
heating	NULL
at	NULL
50°C	NULL
for	NULL
30	NULL
minutes	NULL
in	NULL
a	NULL
buffer	NULL
consisting	NULL
of	NULL
62.5	NULL
mmol/L	NULL
Tris	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
100	NULL
mmol/L	NULL
2-mercaptoethanol	NULL
,	NULL
and	NULL
2	NULL
%	NULL
wt/	NULL
vol	NULL
SDS	NULL
.	NULL

To	NULL
normalize	NULL
for	NULL
protein	NULL
loading	NULL
,	NULL
blots	NULL
were	NULL
reprobed	NULL
with	NULL
anti-Spl	NULL
antibodies	NULL
(	NULL
3.3	NULL
pg/mL	NULL
;	NULL
antibody	NULL
PEP	NULL
2	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
.	NULL

RESULTS	NULL
Expression	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
in	NULL
cell	NULL
lines	NULL
and	NULL
tissues	NULL
.	NULL

We	NULL
initially	NULL
cloned	NULL
BCL-6	NULL
from	NULL
a	NULL
subtracted	NULL
cDNA	NULL
library	NULL
that	NULL
was	NULL
enriched	NULL
in	NULL
genes	NULL
expressed	NULL
in	NULL
the	NULL
Raji	NULL
B-cell	NULL
line	NULL
and	NULL
not	NULL
in	NULL
the	NULL
K562	NULL
erythroleukemia	NULL
cell	NULL
line	NULL
.	NULL
``	NULL

''	NULL
Previous	NULL
studies	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
in	NULL
human	NULL
cell	NULL
lines	NULL
and	NULL
tissues	NULL
have	NULL
yielded	NULL
conflicting	NULL
results	NULL
,	NULL
concluding	NULL
that	NULL
BCL-6	NULL
is	NULL
preferentially	NULL
expressed	NULL
in	NULL
mature	NULL
B	NULL
cells	NULL
,	NULL
``	NULL
is	NULL
preferentially	NULL
expressed	NULL
in	NULL
muscle	NULL
,	NULL
``	NULL
or	NULL
that	NULL
BCL-6	NULL
expression	NULL
is	NULL
ubiquitous	NULL
.	NULL
``	NULL

To	NULL
resolve	NULL
this	NULL
uncertainty	NULL
,	NULL
we	NULL
simultaneously	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

5260	NULL
ALLMAN	NULL
ET	NULL
At	NULL
Mouse	NULL
BCL-6	NULL
M	NULL
A	NULL
S	NULL
P	NULL
A	NULL
D	NULL
S	NULL
C	NULL
I	NULL
Q	NULL
F	NULL
T	NULL
RJH	NULL
A	NULL
S	NULL
D	NULL
V	NULL
L	NULL
L	NULL
N	NULL
L	NULL
N	NULL
R	NULL
L	NULL
R	NULL
S	NULL
R	NULL
D	NULL
I	NULL
L	NULL
T	NULL
D	NULL
v	NULL
v	NULL
I	NULL
V	NULL
v	NULL
Ss	NULL
R	NULL
E	NULL
q	NULL
FoR	NULL
a	NULL
H	NULL
k	NULL
Tt	NULL
v	NULL
L	NULL
}	NULL
so	NULL
Human	NULL
BCL-6	NULL
M	NULL
A	NULL
_	NULL
P	NULL
A	NULL
D	NULL
S	NULL
C	NULL
I	NULL
Q	NULL
F	NULL
T	NULL
RJH	NULL
A	NULL
S	NULL
D	NULL
Vv	NULL
L	NULL
L	NULL
N	NULL
L	NULL
N	NULL
R	NULL
L	NULL
R	NULL
S	NULL
R	NULL
D	NULL
I	NULL
L	NULL
T	NULL
D	NULL
v	NULL
v	NULL
I	NULL
V	NULL
V	NULL
Ss	NULL
R	NULL
E	NULL
Q	NULL
FoR	NULL
A	NULL
k	NULL
Kk	NULL
Tt	NULL
v	NULL
L|	NULL
so	NULL
Mouse	NULL
BCL-6	NULL
|M	NULL
A	NULL
C	NULL
S	NULL
G	NULL
L	NULL
F	NULL
Y	NULL
S	NULL
I	NULL
F	NULL
T	NULL
D	NULL
Q	NULL
L	NULL
K	NULL
C	NULL
N	NULL
L	NULL
S	NULL
v	NULL
I	NULL
N	NULL
L	NULL
D	NULL
PoE	NULL
I	NULL
s	NULL
PE	NULL
G	NULL
F	NULL
C	NULL
I	NULL
L	NULL
L	NULL
D	NULL
F	NULL
M	NULL
Y	NULL
T	NULL
S	NULL
RL	NULL
N	NULL
L	NULL
R	NULL
&	NULL
g	NULL
]	NULL
100	NULL
Human	NULL
BCL-6	NULL
|	NULL
M	NULL
A	NULL
C	NULL
S	NULL
G	NULL
L	NULL
F	NULL
Y	NULL
Ss	NULL
I	NULL
F	NULL
T	NULL
D	NULL
Q	NULL
L	NULL
K	NULL
C	NULL
N	NULL
Lb	NULL
Ss	NULL
v	NULL
I	NULL
N	NULL
L	NULL
DP	NULL
E	NULL
I	NULL
[	NULL
NJP	NULL
E	NULL
src	NULL
I	NULL
L	NULL
L	NULL
D	NULL
F	NULL
M	NULL
Y	NULL
T	NULL
S5	NULL
R	NULL
L	NULL
N	NULL
L	NULL
R	NULL
E	NULL
6	NULL
]	NULL
100	NULL
Mouse	NULL
BCL-6	NULL
|	NULL
N	NULL
I	NULL
M	NULL
A	NULL
V	NULL
M	NULL
T	NULL
T	NULL
A	NULL
M	NULL
Y	NULL
L	NULL
Q	NULL
M	NULL
E	NULL
H	NULL
V	NULL
V	NULL
D	NULL
T	NULL
C	NULL
[	NULL
R	NULL
K	NULL
F	NULL
I	NULL
K	NULL
A	NULL
S	NULL
E	NULL
A	NULL
E	NULL
M	NULL
A	NULL
P	NULL
A	NULL
L	NULL
K	NULL
P	NULL
P	NULL
oR	NULL
E	NULL
E	NULL
F	NULL
L	NULL
NOS	NULL
RM	NULL
L	NULL
Mo	NULL
150	NULL
Human	NULL
BCL-6	NULL
|N	NULL
I	NULL
M	NULL
A	NULL
V	NULL
a	NULL
Mov	NULL
L	NULL
Q	NULL
M	NULL
E	NULL
Hov	NULL
v	NULL
D	NULL
T	NULL
C	NULL
[	NULL
R	NULL
KkoF	NULL
I	NULL
K	NULL
A	NULL
so	NULL
E	NULL
ae	NULL
M	NULL
[	NULL
V_slalk	NULL
rrr	NULL
Es	NULL
r	NULL
L	NULL
Nos	NULL
RM	NULL
L	NULL
#	NULL
150	NULL
Mouse	NULL
BCL-6	NULL
P	NULL
H	NULL
D	NULL
I	NULL
M	NULL
A	NULL
Y	NULL
R	NULL
G	NULL
R	NULL
E	NULL
V	NULL
V	NULL
E	NULL
N	NULL
N	NULL
M	NULL
P	NULL
L	NULL
R	NULL
NOT	NULL
P	NULL
G	NULL
C	NULL
E	NULL
S	NULL
R	NULL
A	NULL
F	NULL
A	NULL
PP	NULL
L	NULL
Y	NULL
s	NULL
G	NULL
L	NULL
S	NULL
T	NULL
PP	NULL
A	NULL
s	NULL
Y	NULL
Pp	NULL
Mov	NULL
s	NULL
Ho	NULL
200	NULL
Human	NULL
sBer-s	NULL
P	NULL
[	NULL
Q	NULL
)	NULL
o	NULL
1	NULL
w	NULL
a	NULL
v	NULL
oR	NULL
so	NULL
R	NULL
Evo	NULL
v	NULL
Eon	NULL
sr	NULL
i	NULL
R	NULL
[	NULL
SCAlr	NULL
s	NULL
coe	NULL
sr	NULL
a	NULL
ra	NULL
r	NULL
@	NULL
u	NULL
yv	NULL
s	NULL
aus	NULL
t	NULL
Pras	NULL
v	NULL
{	NULL
[	NULL
sm	NULL
y	NULL
s	NULL
k	NULL
200	NULL
Mouse	NULL
BCL-6	NULL
LOP	NULL
L	NULL
S	NULL
TOF	NULL
LOF	NULL
S	NULL
D	NULL
E	NULL
E	NULL
L	NULL
R	NULL
D	NULL
A	NULL
P	NULL
R	NULL
M	NULL
P	NULL
V	NULL
A	NULL
NOP	NULL
F	NULL
P	NULL
K	NULL
E	NULL
R	NULL
A	NULL
L	NULL
P	NULL
C	NULL
D	NULL
S	NULL
A	NULL
R	NULL
Q	NULL
V	NULL
P	NULL
N	NULL
E	NULL
Y	NULL
S	NULL
R	NULL
OP	NULL
A	NULL
M	NULL
E	NULL
Vo	NULL
250	NULL
Human	NULL
BCL-6	NULL
LPESELFSDEEERDEBRMPVANPFPKERALPcDSARéIVPmEYSRPEIIEv	NULL
249	NULL
Mouse	NULL
BCL-6	NULL
S	NULL
P	NULL
5	NULL
L	NULL
C	NULL
H	NULL
S	NULL
N	NULL
I	NULL
Y	NULL
S	NULL
P	NULL
Ko	NULL
E	NULL
A_	NULL
V	NULL
P	NULL
E	NULL
E	NULL
A	NULL
RS	NULL
D	NULL
I	NULL
H	NULL
Y	NULL
S	NULL
V	NULL
P	NULL
E	NULL
G	NULL
PK	NULL
P	NULL
A	NULL
V	NULL
P	NULL
S	NULL
A	NULL
R	NULL
N	NULL
A	NULL
PY	NULL
F	NULL
P	NULL
C	NULL
Db	NULL
k	NULL
a	NULL
300	NULL
Human	NULL
BCL-6	NULL
s	NULL
P	NULL
[	NULL
N	NULL
¥Jc	NULL
wos	NULL
N	NULL
I	NULL
v	NULL
s	NULL
Pp	NULL
k	NULL
&	NULL
&	NULL
a	NULL
@	NULL
os	NULL
o	NULL
@	NULL
)	NULL
n	NULL
v	NULL
s	NULL
a	NULL
[	NULL
@	NULL
lp	NULL
s	NULL
a	NULL
R	NULL
n	NULL
a	NULL
rv	NULL
Erp	NULL
c	NULL
b	NULL
k	NULL
A-	NULL
299	NULL
Mouse	NULL
BCL-6	NULL
O5	NULL
k	NULL
E	NULL
E	NULL
E	NULL
R	NULL
P	NULL
S	NULL
S	NULL
E	NULL
D	NULL
E	NULL
I	NULL
A	NULL
L	NULL
HOF	NULL
E	NULL
P	NULL
P	NULL
N	NULL
A	NULL
P	NULL
L	NULL
N	NULL
R	NULL
K	NULL
G	NULL
L	NULL
V	NULL
S	NULL
PQ	NULL
S	NULL
P	NULL
Q	NULL
Kk	NULL
S	NULL
D	NULL
C	NULL
Q	NULL
PN	NULL
5	NULL
P	NULL
T	NULL
Es	NULL
cos	NULL
350	NULL
Human	NULL
BCL-6	NULL
S	NULL
K	NULL
E	NULL
E	NULL
E	NULL
ROP	NULL
S	NULL
S	NULL
E	NULL
D	NULL
E	NULL
I	NULL
A	NULL
L	NULL
H	NULL
F	NULL
E	NULL
P	NULL
P	NULL
N	NULL
A	NULL
P	NULL
L	NULL
N	NULL
OR	NULL
K	NULL
G	NULL
L	NULL
V	NULL
S	NULL
PQS	NULL
P	NULL
Q	NULL
k	NULL
s	NULL
D	NULL
CQ	NULL
PN	NULL
s	NULL
P	NULL
T	NULL
E	NULL
[	NULL
alcs	NULL
349	NULL
Mouse	NULL
BCL-6	NULL
S	NULL
K	NULL
N	NULL
A	NULL
C	NULL
I	NULL
L	NULL
Q	NULL
A	NULL
S	NULL
G	NULL
S	NULL
P	NULL
P	NULL
A	NULL
K	NULL
S	NULL
P	NULL
T	NULL
D	NULL
P	NULL
K	NULL
A	NULL
C	NULL
N	NULL
W	NULL
K	NULL
Ko	NULL
Y	NULL
KOF	NULL
I	NULL
V	NULL
L	NULL
NOS	NULL
L	NULL
N	NULL
Q	NULL
N	NULL
A	NULL
K	NULL
P	NULL
E	NULL
G	NULL
s	NULL
E	NULL
q	NULL
a	NULL
Eo	NULL
400	NULL
Human	NULL
BCL-6	NULL
S	NULL
K	NULL
N	NULL
A	NULL
C	NULL
I	NULL
L	NULL
Q	NULL
A	NULL
S	NULL
G	NULL
S	NULL
P	NULL
P	NULL
A	NULL
K	NULL
oS	NULL
P	NULL
T	NULL
D	NULL
P	NULL
KoA	NULL
C	NULL
N	NULL
W	NULL
K	NULL
Ko	NULL
Y	NULL
K	NULL
oF	NULL
I	NULL
V	NULL
L	NULL
N	NULL
S	NULL
L	NULL
N	NULL
q	NULL
n	NULL
a	NULL
«	NULL
q	NULL
a	NULL
£	NULL
399	NULL
Mouse	NULL
BCL-6	NULL
L	NULL
G	NULL
R	NULL
L	NULL
S	NULL
P	NULL
R	NULL
A	NULL
Y	NULL
P	NULL
A	NULL
P	NULL
P	NULL
A	NULL
C	NULL
Q	NULL
P	NULL
P	NULL
M	NULL
E	NULL
P	NULL
A	NULL
N	NULL
L	NULL
D	NULL
L	NULL
Q	NULL
S	NULL
P	NULL
oT	NULL
K	NULL
L	NULL
S	NULL
A	NULL
§	NULL
G	NULL
E	NULL
DS	NULL
T	NULL
I	NULL
P	NULL
Q	NULL
A	NULL
S	NULL
R	NULL
L	NULL
N	NULL
N	NULL
L	NULL
450	NULL
Human	NULL
BCL-6	NULL
L	NULL
G	NULL
R	NULL
L	NULL
S	NULL
PR	NULL
a	NULL
va	NULL
rer	NULL
a	NULL
coq	NULL
r	NULL
rpm	NULL
E	NULL
P	NULL
[	NULL
EJN	NULL
L	NULL
D	NULL
L	NULL
Q	NULL
s	NULL
PT	NULL
K	NULL
L	NULL
S	NULL
A	NULL
S	NULL
G	NULL
E	NULL
D	NULL
S	NULL
T	NULL
I	NULL
P	NULL
Q	NULL
A	NULL
S	NULL
R	NULL
L	NULL
N	NULL
NI	NULL
]	NULL
449	NULL
Mouse	NULL
BCL-6	NULL
V	NULL
N	NULL
ROS	NULL
LOG	NULL
G	NULL
S	NULL
P	NULL
R	NULL
S	NULL
S	NULL
S	NULL
ES	NULL
HS	NULL
PL	NULL
Y	NULL
M	NULL
H	NULL
OP	NULL
P	NULL
K	NULL
C	NULL
T	NULL
S	NULL
C	NULL
G	NULL
§	NULL
Q	NULL
S5	NULL
P	NULL
Q	NULL
H	NULL
I	NULL
E	NULL
W	NULL
CL	NULL
H	NULL
T	NULL
A	NULL
G6	NULL
P	NULL
T	NULL
F	NULL
P	NULL
Eo	NULL
soo	NULL
Human	NULL
Bct-6	NULL
V	NULL
NOR	NULL
s	NULL
[	NULL
M	NULL
Tho	NULL
s	NULL
pros	NULL
sos	NULL
Eos	NULL
Hos	NULL
PL	NULL
Y	NULL
M	NULL
H	NULL
P	NULL
P	NULL
K	NULL
C	NULL
T	NULL
Ss	NULL
CG	NULL
s	NULL
q	NULL
s	NULL
P	NULL
q	NULL
#	NULL
[	NULL
&	NULL
AJe	NULL
w	NULL
cui	NULL
ow	NULL
t	NULL
a	NULL
a	NULL
P	NULL
t	NULL
F	NULL
[	NULL
AE	NULL
499	NULL
Mouse	NULL
BCL-6	NULL
E	NULL
M	NULL
G	NULL
E	NULL
T	NULL
Q	NULL
S	NULL
E	NULL
Y	NULL
S	NULL
D	NULL
S	NULL
S	NULL
C	NULL
E	NULL
N	NULL
G	NULL
IF	NULL
FJC	NULL
N	NULL
E	NULL
C	NULL
D	NULL
C	NULL
R	NULL
F	NULL
S	NULL
EE	NULL
A	NULL
S	NULL
L	NULL
K	NULL
R	NULL
H	NULL
T	NULL
L	NULL
Q	NULL
T	NULL
H	NULL
Ss	NULL
D	NULL
Kk	NULL
Pv	NULL
k	NULL
c	NULL
o	NULL
}	NULL
sso	NULL
Human	NULL
BCL-6	NULL
E	NULL
M	NULL
G	NULL
E	NULL
T	NULL
Q	NULL
s	NULL
Ev	NULL
s	NULL
Ds	NULL
s	NULL
cE	NULL
N	NULL
s	NULL
[	NULL
@	NULL
)	NULL
lr	NULL
r/c	NULL
N	NULL
&	NULL
c	NULL
b	NULL
c	NULL
R	NULL
Fos	NULL
EoE	NULL
A	NULL
Ss	NULL
£	NULL
K	NULL
R	NULL
H	NULL
T	NULL
L	NULL
Q	NULL
T	NULL
H	NULL
S	NULL
D	NULL
K	NULL
P	NULL
Y	NULL
K	NULL
C	NULL
DJ	NULL
}	NULL
549	NULL
Mouse	NULL
BCL-6	NULL
|R	NULL
C	NULL
Q	NULL
A	NULL
S	NULL
F	NULL
R	NULL
Y	NULL
K	NULL
G	NULL
N	NULL
L	NULL
A	NULL
S	NULL
HOK	NULL
T	NULL
V	NULL
H	NULL
T	NULL
G	NULL
E	NULL
K	NULL
P	NULL
Y	NULL
R	NULL
C	NULL
N	NULL
I	NULL
C	NULL
G	NULL
A	NULL
Q	NULL
F	NULL
N	NULL
R	NULL
P	NULL
A	NULL
N	NULL
L	NULL
KT	NULL
H	NULL
T	NULL
R	NULL
I	NULL
Hos	NULL
G	NULL
Ef	NULL
600	NULL
Human	NULL
BCL-6	NULL
|R	NULL
C	NULL
Q	NULL
A	NULL
S	NULL
F	NULL
R	NULL
Y	NULL
K	NULL
G	NULL
N	NULL
Lb	NULL
A	NULL
S	NULL
H	NULL
K	NULL
T	NULL
V	NULL
H	NULL
T	NULL
G	NULL
E	NULL
K	NULL
P	NULL
Y	NULL
R	NULL
C	NULL
N	NULL
I	NULL
C	NULL
G	NULL
A	NULL
Q	NULL
F	NULL
N	NULL
R	NULL
P	NULL
A	NULL
N	NULL
Lb	NULL
K	NULL
T	NULL
H	NULL
T	NULL
R	NULL
I	NULL
H	NULL
S	NULL
G	NULL
E	NULL
|	NULL
sao	NULL
Mouse	NULL
BCL-6	NULL
|K	NULL
P	NULL
Y	NULL
K	NULL
C	NULL
E	NULL
T	NULL
C	NULL
G	NULL
A	NULL
R	NULL
F	NULL
V	NULL
Q	NULL
V	NULL
A	NULL
H	NULL
L	NULL
R	NULL
A	NULL
H	NULL
V	NULL
L	NULL
I	NULL
HoT	NULL
G	NULL
E	NULL
K	NULL
PY	NULL
PC	NULL
E	NULL
I	NULL
C	NULL
G6	NULL
T	NULL
R	NULL
F	NULL
R	NULL
H	NULL
L	NULL
Q	NULL
T	NULL
L	NULL
kos	NULL
H	NULL
L	NULL
|	NULL
sso	NULL
Human	NULL
BCL-6	NULL
|K	NULL
P	NULL
Y	NULL
K	NULL
C	NULL
E	NULL
T	NULL
C	NULL
G	NULL
A	NULL
R	NULL
F	NULL
V	NULL
Q	NULL
V	NULL
A	NULL
H	NULL
L	NULL
R	NULL
A	NULL
H	NULL
V	NULL
L	NULL
I	NULL
HoT	NULL
G	NULL
E	NULL
K	NULL
PY	NULL
PC	NULL
E	NULL
I	NULL
C	NULL
G	NULL
T	NULL
R	NULL
F	NULL
R	NULL
H	NULL
L	NULL
Q	NULL
T	NULL
L	NULL
Kos	NULL
H	NULL
L	NULL
|	NULL
649	NULL
Mouse	NULL
BCL-6	NULL
|R	NULL
I	NULL
HoT	NULL
G	NULL
E	NULL
K	NULL
P	NULL
Y	NULL
H	NULL
C	NULL
E	NULL
K	NULL
C	NULL
N	NULL
L	NULL
HOF	NULL
R	NULL
H	NULL
K	NULL
S	NULL
Q	NULL
L	NULL
R	NULL
L	NULL
HOL	NULL
R	NULL
Q	NULL
K	NULL
H|G	NULL
A	NULL
I	NULL
T	NULL
N	NULL
T	NULL
K	NULL
v	NULL
Q	NULL
Y	NULL
R	NULL
V	NULL
s	NULL
A	NULL
A	NULL
D	NULL
L	NULL
P	NULL
700	NULL
Human	NULL
BCL-6	NULL
|R	NULL
I	NULL
HoT	NULL
G	NULL
E	NULL
K	NULL
P	NULL
Y	NULL
H	NULL
C	NULL
E	NULL
K	NULL
C	NULL
N	NULL
L	NULL
H	NULL
FOR	NULL
H	NULL
K	NULL
S	NULL
Q	NULL
L	NULL
R	NULL
L	NULL
H	NULL
L	NULL
R	NULL
Q	NULL
K	NULL
Ho	NULL
A	NULL
I	NULL
T	NULL
NT	NULL
kv	NULL
q	NULL
vy	NULL
rvs	NULL
ao	NULL
L	NULL
P	NULL
esq	NULL
Mouse	NULL
BCL-6	NULL
P	NULL
E	NULL
L	NULL
P	NULL
K	NULL
A	NULL
C	NULL
707	NULL
Human	NULL
BCL-6	NULL
P	NULL
E	NULL
L	NULL
P	NULL
K	NULL
A	NULL
C	NULL
706	NULL
Fig	NULL
2	NULL
.	NULL

-	NULL
Deduced	NULL
amino	NULL
acid	NULL
sequence	NULL
and	NULL
tissue	NULL
expression	NULL
of	NULL
mouse	NULL
BCL-6	NULL
.	NULL

Amino-terminal	NULL
POZ	NULL
and	NULL
carboxy-terminal	NULL
zinc-finger	NULL
domains	NULL
are	NULL
boxed	NULL
and	NULL
positions	NULL
differing	NULL
between	NULL
mouse	NULL
and	NULL
human	NULL
are	NULL
indicated	NULL
by	NULL
enclosed	NULL
human	NULL
residues	NULL
.	NULL

compared	NULL
the	NULL
levels	NULL
of	NULL
BCL-6	NULL
in	NULL
human	NULL
cell	NULL
lines	NULL
and	NULL
tissues	NULL
on	NULL
the	NULL
same	NULL
Northern	NULL
blot	NULL
(	NULL
Fig	NULL
1A	NULL
)	NULL
.	NULL

We	NULL
detected	NULL
BCL-6	NULL
mRNA	NULL
readily	NULL
in	NULL
some	NULL
,	NULL
but	NULL
not	NULL
all	NULL
,	NULL
mature	NULL
B-cell	NULL
lines	NULL
(	NULL
Fig	NULL
1A	NULL
,	NULL
lanes	NULL
6	NULL
through	NULL
11	NULL
)	NULL
.	NULL

BCL-6	NULL
was	NULL
also	NULL
found	NULL
to	NULL
be	NULL
highly	NULL
expressed	NULL
in	NULL
3	NULL
additional	NULL
mature	NULL
B-cell	NULL
lines	NULL
and	NULL
in	NULL
one	NULL
of	NULL
two	NULL
pre-B-cell	NULL
lines	NULL
tested	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

BCL-6	NULL
mRNA	NULL
levels	NULL
were	NULL
low	NULL
in	NULL
T-cell	NULL
,	NULL
myeloid	NULL
,	NULL
and	NULL
erythroid	NULL
and	NULL
HeLa	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
1A	NULL
,	NULL
lanes	NULL
1	NULL
through	NULL
5	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

BCL-6	NULL
mRNA	NULL
was	NULL
detected	NULL
in	NULL
all	NULL
tissues	NULL
tested	NULL
,	NULL
with	NULL
only	NULL
minor	NULL
quantitative	NULL
differences	NULL
between	NULL
tissues	NULL
(	NULL
Fig	NULL
1	NULL
A	NULL
,	NULL
lanes	NULL
12	NULL
through	NULL
17	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
in	NULL
certain	NULL
B-lymphoma	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
1A	NULL
,	NULL
Raji	NULL
and	NULL
BJAB	NULL
)	NULL
were	NULL
not	NULL
notably	NULL
higher	NULL
than	NULL
tissue	NULL
levels	NULL
.	NULL

Rather	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
is	NULL
downregulated	NULL
in	NULL
many	NULL
cell	NULL
lines	NULL
when	NULL
compared	NULL
with	NULL
expression	NULL
in	NULL
tissues	NULL
.	NULL

Although	NULL
BCL-6	NULL
is	NULL
generally	NULL
expressed	NULL
at	NULL
high	NULL
levels	NULL
in	NULL
many	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
B-cell	NULL
lines	NULL
(	NULL
Fig	NULL
1A	NULL
and	NULL
B	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
it	NULL
was	NULL
peculiarly	NULL
absent	NULL
from	NULL
six	NULL
mature	NULL
B-cell	NULL
lines	NULL
,	NULL
four	NULL
of	NULL
which	NULL
were	NULL
long-term	NULL
B-lymphoblastoid	NULL
cell	NULL
lines	NULL
(	NULL
LCLs	NULL
)	NULL
transformed	NULL
with	NULL
EBV	NULL
(	NULL
Fig	NULL
1A	NULL
,	NULL
MBBI1	NULL
and	NULL
VDSO	NULL
;	NULL
and	NULL
Fig	NULL
1B	NULL
,	NULL
LCL-2	NULL
and	NULL
LCL-4	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
provided	NULL
a	NULL
clue	NULL
to-	NULL
possible	NULL
regulation	NULL
of	NULL
BCL-6	NULL
during	NULL
lymphocyte	NULL
activation	NULL
because	NULL
previous	NULL
studies	NULL
of	NULL
LCLs	NULL
have	NULL
shown	NULL
that	NULL
they	NULL
have	NULL
an	NULL
activated	NULL
B-cell	NULL
phenotype	NULL
.	NULL
``	NULL

''	NULL
``	NULL
'	NULL
EBV-encoded	NULL
proteins	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
drive	NULL
expression	NULL
of	NULL
cell	NULL
surface	NULL
markers	NULL
that	NULL
are	NULL
upregulated	NULL
after	NULL
antigenic	NULL
activation	NULL
of	NULL
normal	NULL
resting	NULL
B	NULL
cells	NULL
,	NULL
``	NULL
``	NULL
and	NULL
thus	NULL
it	NULL
was	NULL
conceivable	NULL
that	NULL
BCL-6	NULL
would	NULL
be	NULL
similarly	NULL
modulated	NULL
.	NULL

This	NULL
hypothesis	NULL
led	NULL
us	NULL
to	NULL
investigate	NULL
the	NULL
expression	NULL
of	NULL
BCL	NULL
-6	NULL
in	NULL
the	NULL
type	NULL
I	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
line	NULL
,	NULL
Akata	NULL
.	NULL
``	NULL

Akata	NULL
cells	NULL
contain	NULL
EBV	NULL
in	NULL
a	NULL
latent	NULL
state	NULL
in	NULL
which	NULL
only	NULL
the	NULL
EBNA1	NULL
gene	NULL
product	NULL
is	NULL
expressed	NULL
.	NULL
``	NULL

However	NULL
,	NULL
when	NULL
Akata	NULL
cells	NULL
are	NULL
stimulated	NULL
by	NULL
cross-linking	NULL
of	NULL
their	NULL
surface	NULL
Ig	NULL
receptors	NULL
,	NULL
the	NULL
EBV	NULL
lytic	NULL
cycle	NULL
is	NULL
initiated	NULL
and	NULL
the	NULL
cells	NULL
express	NULL
several	NULL
of	NULL
the	NULL
EBV	NULL
gene	NULL
products	NULL
that	NULL
are	NULL
constituitively	NULL
expressed	NULL
in	NULL
LCLs	NULL
.	NULL

Activation	NULL
of	NULL
Akata	NULL
cells	NULL
in	NULL
this	NULL
fashion	NULL
led	NULL
to	NULL
the	NULL
downmodulation	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

BCL-6	NULL
mRNA	NULL
expression	NULL
during	NULL
activation	NULL
of	NULL
resting	NULL
B	NULL
lymphocytes	NULL
.	NULL

These	NULL
observations	NULL
led	NULL
us	NULL
to	NULL
investigate	NULL
BCL-6	NULL
mRNA	NULL
levels	NULL
during	NULL
activation	NULL
of	NULL
resting	NULL
B	NULL
lymphocytes	NULL
.	NULL

To	NULL
perform	NULL
this	NULL
analysis	NULL
with	NULL
mouse	NULL
as	NULL
well	NULL
as	NULL
human	NULL
B	NULL
lymphocytes	NULL
,	NULL
we	NULL
cloned	NULL
the	NULL
mouse	NULL
BCL-6	NULL
gene	NULL
by	NULL
low	NULL
stringency	NULL
hybridization	NULL
with	NULL
a	NULL
human	NULL
BCL-6	NULL
probe	NULL
.	NULL

Sequencing	NULL
of	NULL
a	NULL
3.5-kb	NULL
mouse	NULL
BCL-6	NULL
cDNA	NULL
clone	NULL
showed	NULL
striking	NULL
homology	NULL
to	NULL
human	NULL
BCL-6	NULL
;	NULL
the	NULL
predicted	NULL
amino	NULL
acid	NULL
sequences	NULL
from	NULL
the	NULL
cDNAs	NULL
are	NULL
94	NULL
%	NULL
identical	NULL
(	NULL
Fig	NULL
2	NULL
)	NULL
.	NULL

The	NULL
regions	NULL
of	NULL
highest	NULL
sequence	NULL
conservation	NULL
were	NULL
the	NULL
zinc	NULL
finger	NULL
domain	NULL
(	NULL
100	NULL
%	NULL
identity	NULL
)	NULL
and	NULL
the	NULL
POZ	NULL
domain	NULL
(	NULL
98	NULL
%	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BCL-6	NULL
EXPRESSION	NULL
DURING	NULL
B-CELL	NULL
ACTIVATION	NULL
A	NULL
GAPDH	NULL
-	NULL
#	NULL
#	NULL
us	NULL
UP	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
B	NULL
BCL-6/GAPDH	NULL
BCL-6	NULL
0.4	NULL
Mouse	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
Human	NULL
Control	NULL
anti-lIgM	NULL
LPS	NULL
Control	NULL
PMA	NULL
+	NULL
lono	NULL
.	NULL

Control	NULL
a	NULL
°f	NULL
3	NULL
50	NULL
6	NULL
%	NULL
STIMULUS	NULL
CD40L	NULL
anti-lgM	NULL
+	NULL
CD4OL	NULL
£	NULL
C	NULL
6	NULL
O	NULL
SAC	NULL
+	NULL
IL-2	NULL
anti-lIgM	NULL
5261	NULL
Mouse	NULL
Human	NULL
-_	NULL
]	NULL
(	NULL
am	NULL
]	NULL
q-6	NULL
=	NULL
f	NULL
,	NULL
=	NULL
.	NULL

%	NULL
4	NULL
we	NULL
-	NULL
O	NULL
-A-	NULL
-	NULL
oe	NULL
0	NULL
o	NULL
2	NULL
I	NULL
20	NULL
2	NULL
05	NULL
o	NULL
913	NULL
§S	NULL
58	NULL
Seeds	NULL
59	NULL
C	NULL
C	NULL
.	NULL

am	NULL
C	NULL
O	NULL
®	NULL
_	NULL
O	NULL
A	NULL
O	NULL
s	NULL
O	NULL
as	NULL
O	NULL
a	NULL
(	NULL
DC/3g	NULL
I	NULL
:	NULL
ﬁ	NULL
o	NULL
«	NULL
s	NULL
``	NULL
®	NULL
@	NULL
~-~~	NULL
#	NULL
8	NULL
-am	NULL
-s	NULL
©	NULL
Gt	NULL
12	NULL
13	NULL
14	NULL
Fig	NULL
3	NULL
.	NULL

BCL-6	NULL
mRNA	NULL
expression	NULL
in	NULL
activated	NULL
mouse	NULL
and	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Northern	NULL
blot	NULL
analysis	NULL
for	NULL
BCL-6	NULL
and	NULL
GAPDH	NULL
expression	NULL
using	NULL
total	NULL
RNA	NULL
from	NULL
T-depleted	NULL
mouse	NULL
splenocytes	NULL
(	NULL
lanes	NULL
1	NULL
through	NULL
11	NULL
)	NULL
cultured	NULL
with	NULL
anti-lgM	NULL
,	NULL
LPS	NULL
,	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
,	NULL
.	NULL

anti-lgD-dextran	NULL
,	NULL
or	NULL
CD40	NULL
ligand	NULL
,	NULL
with	NULL
and	NULL
without	NULL
anti-lIgM	NULL
for	NULL
24	NULL
hours	NULL
,	NULL
or	NULL
human	NULL
peripheral	NULL
blood	NULL
B	NULL
cells	NULL
(	NULL
lanes	NULL
12	NULL
through	NULL
14	NULL
)	NULL
cultured	NULL
with	NULL
anti-IgM	NULL
or	NULL
SAC	NULL
plus	NULL
rIL-2	NULL
for	NULL
44	NULL
hours	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Quantitation	NULL
of	NULL
the	NULL
BCL-6/GAPDH	NULL
ratio	NULL
from	NULL
the	NULL
Northern	NULL
blots	NULL
in	NULL
(	NULL
A	NULL
)	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

5262	NULL
ALLMAN	NULL
ET	NULL
AL	NULL
BCL-6	NULL
GAPDH	NULL
-	NULL
$	NULL
--	NULL
at	NULL
ab	NULL
#	NULL
«	NULL
#	NULL
#	NULL
4	NULL
5	NULL
6	NULL
7	NULL
1	NULL
2	NULL
3	NULL
B	NULL
E	NULL
'	NULL
C	NULL
'	NULL
C	NULL
'	NULL
C	NULL
'	NULL
C'CO	NULL
_C.C_C_C_Co	NULL
o	NULL
N0	NULL
0	NULL
0	NULL
O	NULL
O	NULL
ip	NULL
0	NULL
O0	NULL
O	NULL
O	NULL
O	NULL
ip	NULL
O	NULL
O	NULL
CO	NULL
~-	NULL
r	NULL
Expt	NULL
.	NULL

1	NULL
0.47	NULL
1.0	NULL
TC	NULL
a	NULL
03~	NULL
0.757	NULL
ra	NULL
<	NULL
$	NULL
o	NULL
»	NULL
_J	NULL
[	NULL
6	NULL
]	NULL
m	NULL
0.1-	NULL
0.25	NULL
o-	NULL
R	NULL
0	NULL
0.5	NULL
1	NULL
2	NULL
4	NULL
8	NULL
16	NULL
TIME	NULL
(	NULL
hours	NULL
)	NULL
identity	NULL
)	NULL
.	NULL

This	NULL
high	NULL
degree	NULL
of	NULL
sequence	NULL
homology	NULL
suggests	NULL
that	NULL
the	NULL
mouse	NULL
and	NULL
human	NULL
proteins	NULL
function	NULL
analogously	NULL
and	NULL
,	NULL
in	NULL
particular	NULL
,	NULL
share	NULL
equivalent	NULL
sequence-specific	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

The	NULL
mouse	NULL
BCL-6	NULL
cDNA	NULL
was	NULL
used	NULL
to	NULL
probe	NULL
a	NULL
Northern	NULL
blot	NULL
of	NULL
mouse	NULL
tissue	NULL
mRNA	NULL
and	NULL
,	NULL
as	NULL
with	NULL
human	NULL
BCL-6	NULL
,	NULL
BCL-6	NULL
mRNA	NULL
was	NULL
detected	NULL
at	NULL
comparable	NULL
levels	NULL
in	NULL
all	NULL
tissues	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
BCL-6	NULL
expression	NULL
during	NULL
B-cell	NULL
activation	NULL
,	NULL
we	NULL
purified	NULL
B	NULL
lymphocytes	NULL
from	NULL
mouse	NULL
spleen	NULL
and	NULL
human	NULL
peripheral	NULL
blood	NULL
,	NULL
because	NULL
the	NULL
vast	NULL
majority	NULL
of	NULL
lymphocytes	NULL
in	NULL
these	NULL
sites	NULL
are	NULL
in	NULL
the	NULL
GO	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL
``	NULL

BCL-6	NULL
mRNA	NULL
was	NULL
readily	NULL
detected	NULL
in	NULL
unstimulated	NULL
mouse	NULL
and	NULL
human	NULL
B	NULL
cells	NULL
(	NULL
Fig	NULL
3A	NULL
,	NULL
lanes	NULL
1	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
and	NULL
12	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
cultures	NULL
of	NULL
mouse	NULL
B	NULL
cells	NULL
stimulated	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
mitogenic	NULL
agents	NULL
(	NULL
anti-IgM	NULL
antibodies	NULL
,	NULL
LPS	NULL
,	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
,	NULL
anti-IgD	NULL
antibodies	NULL
coupled	NULL
to	NULL
dextran	NULL
,	NULL
CD40	NULL
ligand	NULL
,	NULL
or	NULL
CD40	NULL
ligand	NULL
plus	NULL
anti-IgM	NULL
antibodies	NULL
)	NULL
exhibited	NULL
marked	NULL
reductions	NULL
in	NULL
BCL-6	NULL
mRNA	NULL
levels	NULL
24	NULL
hours	NULL
after	NULL
stimulation	NULL
0	NULL
0.5	NULL
1°	NULL
2	NULL
4	NULL
8	NULL
16	NULL
Fig	NULL
4	NULL
.	NULL

-	NULL
Kinetics	NULL
of	NULL
BCL-6	NULL
downregulation	NULL
after	NULL
stimulation	NULL
with	NULL
anti-lIgM	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Northern	NULL
blot	NULL
analysis	NULL
for	NULL
BCL-6	NULL
and	NULL
GAPDH	NULL
expression	NULL
of	NULL
total	NULL
RNA	NULL
from	NULL
mouse	NULL
splenic	NULL
B	NULL
cells	NULL
stimulated	NULL
for	NULL
the	NULL
indicated	NULL
durations	NULL
with	NULL
anti-lIgM	NULL
antibodies	NULL
in	NULL
two	NULL
separate	NULL
ex-periments	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Quantitation	NULL
of	NULL
the	NULL
BCL-6/GAPDH	NULL
ratio	NULL
from	NULL
the	NULL
Northern	NULL
blots	NULL
in	NULL
(	NULL
A	NULL
)	NULL
.	NULL

(	NULL
Fig	NULL
3A	NULL
)	NULL
.	NULL

Quantitative	NULL
analyses	NULL
of	NULL
these	NULL
blots	NULL
indicated	NULL
that	NULL
activation	NULL
with	NULL
these	NULL
stimuli	NULL
resulted	NULL
in	NULL
a	NULL
77	NULL
%	NULL
to	NULL
97	NULL
%	NULL
reduction	NULL
in	NULL
BCL-6	NULL
expression	NULL
(	NULL
Fig	NULL
3B	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
reduction	NULL
in	NULL
BCL-6	NULL
expression	NULL
was	NULL
observed	NULL
after	NULL
44	NULL
hours	NULL
of	NULL
stimulation	NULL
of	NULL
human	NULL
B	NULL
cells	NULL
with	NULL
SAC	NULL
plus	NULL
IL-2	NULL
or	NULL
anti-IgM	NULL
antibodies	NULL
(	NULL
Fig	NULL
3A	NULL
)	NULL
.	NULL

At	NULL
this	NULL
late	NULL
time	NULL
point	NULL
after	NULL
activation	NULL
,	NULL
the	NULL
B	NULL
cells	NULL
should	NULL
be	NULL
cycling	NULL
asynchronously	NULL
,	NULL
suggesting	NULL
that	NULL
BCL-6	NULL
mRNA	NULL
levels	NULL
remain	NULL
reduced	NULL
in	NULL
G1	NULL
,	NULL
S	NULL
,	NULL
G2	NULL
,	NULL
and	NULL
M	NULL
phases	NULL
of	NULL
in	NULL
vitro-activated	NULL
B	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
we	NULL
can	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
BCL-6	NULL
might	NULL
be	NULL
transiently	NULL
elevated	NULL
during	NULL
some	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
in	NULL
these	NULL
cultures	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
kinetics	NULL
of	NULL
BCL-6	NULL
downregulation	NULL
,	NULL
we	NULL
investigated	NULL
BCL-6	NULL
mRNA	NULL
expression	NULL
at	NULL
multiple	NULL
time	NULL
points	NULL
after	NULL
anti-IgM	NULL
stimulation	NULL
of	NULL
mouse	NULL
splenic	NULL
B	NULL
cells	NULL
.	NULL

BCL-6	NULL
expression	NULL
declined	NULL
markedly	NULL
at	NULL
8	NULL
hours	NULL
after	NULL
stimulation	NULL
and	NULL
,	NULL
by	NULL
16	NULL
hours	NULL
,	NULL
was	NULL
reduced	NULL
to	NULL
2	NULL
%	NULL
to	NULL
19	NULL
%	NULL
of	NULL
the	NULL
levels	NULL
in	NULL
resting	NULL
lymphocytes	NULL
(	NULL
Fig	NULL
4A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

The	NULL
modest	NULL
decrease	NULL
in	NULL
BCL-6	NULL
expression	NULL
at	NULL
the	NULL
0.5-	NULL
,	NULL
1-	NULL
,	NULL
2-	NULL
,	NULL
and	NULL
4-hour	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BCL-6	NULL
EXPRESSION	NULL
DURING	NULL
B-CELL	NULL
ACTIVATION	NULL
O	NULL
S	NULL
10000	NULL
F	NULL
<	NULL
g	NULL
8000	NULL
4	NULL
A.	NULL
CC	NULL
O	NULL
QO	NULL
-	NULL
e000	NULL
-	NULL
-e-	NULL
Control	NULL
<	NULL
-e-	NULL
anti-IgM	NULL
W	NULL
<	NULL
A	NULL
41001	NULL
pS	NULL
y=	NULL
T	NULL
E-	NULL
_	NULL
20004	NULL
kal	NULL
L	NULL
o	NULL
0	NULL
f	NULL
t	NULL
t	NULL
r	NULL
r	NULL
y	NULL
t	NULL
r	NULL
--	NULL
10	NULL
14	NULL
18	NULL
22	NULL
26	NULL
30	NULL
34	NULL
38	NULL
42	NULL
46	NULL
50	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
Fig	NULL
4	NULL
.	NULL

-	NULL
(	NULL
cont	NULL
'd	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
DNA	NULL
synthesis	NULL
analysis	NULL
of	NULL
anti-lgM-stimulated	NULL
mouse	NULL
splenic	NULL
B	NULL
cells	NULL
.	NULL

B	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
quadruplicate	NULL
without	NULL
or	NULL
with	NULL
anti-ligM	NULL
antibodies	NULL
at	NULL
50	NULL
ug/ml	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
peri-ods	NULL
.	NULL

All	NULL
cultures	NULL
were	NULL
pulsed	NULL
with	NULL
for	NULL
the	NULL
final	NULL
4	NULL
hours	NULL
of	NULL
culture	NULL
and	NULL
harvested	NULL
at	NULL
the	NULL
indicated	NULL
time	NULL
points	NULL
.	NULL

time	NULL
points	NULL
in	NULL
experiment	NULL
1	NULL
(	NULL
Fig	NULL
4B	NULL
)	NULL
was	NULL
not	NULL
a	NULL
consistent	NULL
finding	NULL
(	NULL
Fig	NULL
4B	NULL
,	NULL
experiment	NULL
2	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
timing	NULL
of	NULL
the	NULL
downregulation	NULL
of	NULL
BCL-6	NULL
relative	NULL
to	NULL
entry	NULL
into	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
parallel	NULL
cultures	NULL
were	NULL
pulsed	NULL
for	NULL
4	NULL
hours	NULL
at	NULL
multiple	NULL
time	NULL
points	NULL
after	NULL
anti-Ig	NULL
M	NULL
treatment	NULL
.	NULL

DNA	NULL
synthesis	NULL
began	NULL
20	NULL
to	NULL
22	NULL
hours	NULL
after	NULL
stimulation	NULL
,	NULL
12	NULL
hours	NULL
after	NULL
BCL6	NULL
mRNA	NULL
levels	NULL
began	NULL
to	NULL
decline	NULL
,	NULL
and	NULL
4	NULL
hours	NULL
after	NULL
BCL-6	NULL
expression	NULL
was	NULL
severely	NULL
reduced	NULL
(	NULL
Fig	NULL
4C	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
during	NULL
in	NULL
vitro	NULL
mitogenic	NULL
activation	NULL
of	NULL
B	NULL
cells	NULL
,	NULL
BCL-6	NULL
expression	NULL
decreased	NULL
during	NULL
the	NULL
mid-G1	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
before	NULL
entry	NULL
into	NULL
S	NULL
phase	NULL
.	NULL

BCL-6	NULL
expression	NULL
during	NULL
T-lymphocyte	NULL
activation	NULL
.	NULL

Because	NULL
BCL-6	NULL
was	NULL
expressed	NULL
in	NULL
human	NULL
and	NULL
mouse	NULL
thymus	NULL
(	NULL
Fig	NULL
1A	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
we	NULL
considered	NULL
the	NULL
possibility	NULL
that	NULL
BCL-6	NULL
mRNA	NULL
levels	NULL
might	NULL
be	NULL
modulated	NULL
after	NULL
activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

To	NULL
test	NULL
this	NULL
notion	NULL
,	NULL
resting	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
were	NULL
polyclonally	NULL
activated	NULL
with	NULL
PHA	NULL
.	NULL

BCL-6	NULL
mRNA	NULL
was	NULL
detectable	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
and	NULL
persisted	NULL
for	NULL
4	NULL
hours	NULL
after	NULL
PHA	NULL
stimulation	NULL
(	NULL
Fig	NULL
5A	NULL
)	NULL
.	NULL

However	NULL
,	NULL
by	NULL
10	NULL
to	NULL
16	NULL
hours	NULL
of	NULL
culture	NULL
with	NULL
PHA	NULL
,	NULL
BCL-6	NULL
levels	NULL
had	NULL
declined	NULL
markedly	NULL
and	NULL
remained	NULL
low	NULL
thereafter	NULL
,	NULL
up	NULL
to	NULL
and	NULL
including	NULL
47	NULL
hours	NULL
after	NULL
stimulation	NULL
.	NULL

DNA	NULL
content	NULL
analysis	NULL
indicated	NULL
that	NULL
S	NULL
phase	NULL
and	NULL
G2/M	NULL
phase	NULL
were	NULL
reached	NULL
by	NULL
16	NULL
and	NULL
22	NULL
hours	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
by	NULL
46	NULL
hours	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
apparently	NULL
progressing	NULL
through	NULL
the	NULL
cell	NULL
cycle	NULL
asynchronously	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
show	NULL
that	NULL
,	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
as	NULL
in	NULL
B	NULL
cells	NULL
,	NULL
BCL-6	NULL
was	NULL
downregulated	NULL
after	NULL
mitogenic	NULL
activation	NULL
before	NULL
entry	NULL
into	NULL
S	NULL
phase	NULL
.	NULL

Expression	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
and	NULL
protein	NULL
in	NULL
activated	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
.	NULL

T-cell-dependent	NULL
activation	NULL
of	NULL
B	NULL
cells	NULL
leads	NULL
to	NULL
the	NULL
formation	NULL
of	NULL
germinal	NULL
centers	NULL
.	NULL
``	NULL

Recent	NULL
immunohistochemical	NULL
analyses	NULL
of	NULL
human	NULL
lymphoid	NULL
tissues	NULL
using	NULL
anti-BCL-6	NULL
antibodies	NULL
showed	NULL
strong	NULL
and	NULL
selective	NULL
5263	NULL
expression	NULL
of	NULL
BCL-6	NULL
protein	NULL
in	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
.	NULL
``	NULL

To	NULL
understand	NULL
the	NULL
molecular	NULL
basis	NULL
of	NULL
this	NULL
selective	NULL
expression	NULL
,	NULL
we	NULL
compared	NULL
BCL-6	NULL
mRNA	NULL
levels	NULL
in	NULL
resting	NULL
human	NULL
peripheral	NULL
blood	NULL
B	NULL
cells	NULL
and	NULL
activated	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
from	NULL
human	NULL
tonsils	NULL
.	NULL

Surprisingly	NULL
,	NULL
both	NULL
B-cell	NULL
subsets	NULL
were	NULL
found	NULL
to	NULL
express	NULL
BCL-6	NULL
mRNA	NULL
comparably	NULL
(	NULL
Fig	NULL
6B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
antigen-stimulated	NULL
B	NULL
cells	NULL
that	NULL
enter	NULL
the	NULL
germinal	NULL
center	NULL
microenvironment	NULL
do	NULL
not	NULL
downregulate	NULL
BCL-6	NULL
mRNA	NULL
expression	NULL
as	NULL
do	NULL
B	NULL
cells	NULL
activated	NULL
in	NULL
vitro	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
expressed	NULL
considerably	NULL
more	NULL
BCL-6	NULL
protein	NULL
than	NULL
did	NULL
resting	NULL
B	NULL
cells	NULL
,	NULL
as	NULL
judged	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
(	NULL
Fig	NULL
6A	NULL
,	NULL
B	NULL
,	NULL
and	NULL
C	NULL
)	NULL
.	NULL

BCL-6	NULL
protein	NULL
was	NULL
readily	NULL
detectable	NULL
in	NULL
germinal	NULL
center	NULL
cells	NULL
(	NULL
Fig	NULL
6A	NULL
)	NULL
and	NULL
in	NULL
B-cell	NULL
lines	NULL
that	NULL
express	NULL
BCL-6	NULL
mRNA	NULL
(	NULL
Fig	NULL
6A	NULL
,	NULL
BJAB	NULL
and	NULL
RL	NULL
)	NULL
,	NULL
but	NULL
not	NULL
in	NULL
B-cell	NULL
lines	NULL
that	NULL
express	NULL
little	NULL
or	NULL
no	NULL
BCL	NULL
6	NULL
mRNA	NULL
(	NULL
Fig	NULL
6A	NULL
,	NULL
VDSO	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
BCL-6	NULL
protein	NULL
expression	NULL
in	NULL
germinal	NULL
center	NULL
cells	NULL
and	NULL
B-cell	NULL
lines	NULL
was	NULL
roughly	NULL
equivalent	NULL
.	NULL

The	NULL
BCL-6	NULL
protein	NULL
from	NULL
germinal	NULL
center	NULL
cells	NULL
migrated	NULL
slower	NULL
in	NULL
SDS-PAGE	NULL
gel	NULL
than	NULL
BCL-6	NULL
protein	NULL
generated	NULL
by	NULL
in	NULL
vitro	NULL
translation	NULL
(	NULL
Fig	NULL
6A	NULL
,	NULL
compare	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Because	NULL
phosphorylation	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
alter	NULL
the	NULL
mobility	NULL
of	NULL
BCL-6	NULL
protein	NULL
(	NULL
Onizuka	NULL
et	NULL
al	NULL
``	NULL
and	NULL
A.D.	NULL
,	NULL
unpublished	NULL
observations	NULL
)	NULL
,	NULL
this	NULL
finding	NULL
suggests	NULL
that	NULL
BCL-6	NULL
is	NULL
a	NULL
phosphoprotein	NULL
in	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
the	NULL
most	NULL
interesting	NULL
finding	NULL
was	NULL
that	NULL
germinal	NULL
center	NULL
cells	NULL
expressed	NULL
threefold	NULL
to	NULL
34-fold	NULL
more	NULL
BCL-6	NULL
protein	NULL
than	NULL
resting	NULL
B	NULL
cells	NULL
,	NULL
even	NULL
though	NULL
the	NULL
BCL-6	NULL
mRNA	NULL
levels	NULL
were	NULL
similar	NULL
(	NULL
Fig	NULL
6B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
showed	NULL
that	NULL
the	NULL
elevated	NULL
expression	NULL
of	NULL
BCL-6	NULL
protein	NULL
in	NULL
activated	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
is	NULL
not	NULL
primarily	NULL
regulated	NULL
by	NULL
changes	NULL
in	NULL
steady-state	NULL
mRNA	NULL
levels	NULL
.	NULL

DISCUSSION	NULL
We	NULL
report	NULL
here	NULL
that	NULL
expression	NULL
of	NULL
the	NULL
proto-oncogene	NULL
BCL-6	NULL
is	NULL
modulated	NULL
during	NULL
mitogenic	NULL
stimulation	NULL
of	NULL
lymphocytes	NULL
in	NULL
vitro	NULL
.	NULL

The	NULL
highest	NULL
levels	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
were	NULL
observed	NULL
in	NULL
resting	NULL
B	NULL
and	NULL
T	NULL
lymphocytes	NULL
.	NULL

Stimulation	NULL
of	NULL
lymphocytes	NULL
by	NULL
diverse	NULL
mitogenic	NULL
agents	NULL
led	NULL
to	NULL
profound	NULL
decreases	NULL
in	NULL
BCL-6	NULL
expression	NULL
in	NULL
mid	NULL
to	NULL
late	NULL
G1	NULL
phase	NULL
.	NULL

BCL-6	NULL
levels	NULL
remained	NULL
low	NULL
thereafter	NULL
,	NULL
even	NULL
in	NULL
cultures	NULL
of	NULL
asynchronously	NULL
dividing	NULL
cells	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
activated	NULL
B	NULL
lymphocytes	NULL
derived	NULL
from	NULL
human	NULL
germinal	NULL
centers	NULL
maintained	NULL
high	NULL
BCL-6	NULL
mRNA	NULL
levels	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
regulation	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
expression	NULL
during	NULL
lymphocyte	NULL
activation	NULL
depends	NULL
critically	NULL
on	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
activation	NULL
signal	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
have	NULL
presented	NULL
evidence	NULL
that	NULL
BCL-6	NULL
protein	NULL
expression	NULL
is	NULL
regulated	NULL
independently	NULL
of	NULL
mRNA	NULL
expression	NULL
to	NULL
achieve	NULL
selective	NULL
and	NULL
high-level	NULL
expression	NULL
of	NULL
BCL-6	NULL
protein	NULL
in	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
first	NULL
indication	NULL
that	NULL
BCL-6	NULL
expression	NULL
might	NULL
be	NULL
regulated	NULL
in	NULL
B	NULL
lymphocytes	NULL
came	NULL
from	NULL
the	NULL
observation	NULL
that	NULL
EBV-transformed	NULL
LCL	NULL
s	NULL
did	NULL
not	NULL
express	NULL
BCL-6	NULL
,	NULL
whereas	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
lines	NULL
had	NULL
high	NULL
levels	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
.	NULL

Indeed	NULL
,	NULL
three	NULL
other	NULL
independently	NULL
isolated	NULL
LCLs	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
lack	NULL
BCL-6	NULL
mRNA	NULL
.	NULL
``	NULL

LCL	NULL
s	NULL
differ	NULL
from	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
lines	NULL
in	NULL
that	NULL
LCLs	NULL
express	NULL
a	NULL
set	NULL
of	NULL
EBV	NULL
gene	NULL
products	NULL
that	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
transcriptionally	NULL
activate	NULL
a	NULL
variety	NULL
of	NULL
cellular	NULL
genes	NULL
(	NULL
for	NULL
review	NULL
see	NULL
Klein	NULL
``	NULL
)	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
LCLs	NULL
express	NULL
the	NULL
EBV	NULL
membrane	NULL
protein	NULL
LMP1	NULL
that	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

5264	NULL
PHA	NULL
:	NULL
i	NULL
£	NULL
BCL-6	NULL
-	NULL
»	NULL
«	NULL
®	NULL
«	NULL
«	NULL
ALLMAN	NULL
ET	NULL
AL	NULL
Expt	NULL
.	NULL

3	NULL
®	NULL
12	NULL
hr	NULL
16	NULL
hr	NULL
24	NULL
hr	NULL
%	NULL
48	NULL
hr	NULL
R	NULL
8	NULL
hr	NULL
L	NULL
L	NULL
C	NULL
C	NULL
-	NULL
*f	NULL
wo	NULL
w	NULL
»	NULL
ie	NULL
GAPDH	NULL
-	NULL
#	NULL
#	NULL
W	NULL
@	NULL
bip	NULL
@	NULL
@	NULL
eenece	NULL
Cm	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9101112	NULL
131415161718	NULL
1920	NULL
B	NULL
Expt	NULL
.	NULL

1	NULL
Expt	NULL
.	NULL

2	NULL
Expt	NULL
.	NULL

3	NULL
of	NULL
)	NULL
``	NULL
O	NULL
y-	NULL
&	NULL
:	NULL
L	NULL
Q	NULL
a_	NULL
<	NULL
[	NULL
6	NULL
]	NULL
~-p	NULL
md	NULL
O	NULL
co	NULL
I	NULL
I	NULL
I	NULL
U	NULL
I	NULL
0	NULL
1	NULL
14	NULL
22	NULL
46	NULL
0	NULL
23	NULL
1	NULL
2	NULL
No	NULL
Stim	NULL
.	NULL

10	NULL
23	NULL
47	NULL
BCL-6/GAPDH	NULL
1	NULL
--	NULL
-4	NULL
8	NULL
12	NULL
16	NULL
24	NULL
48	NULL
TIME	NULL
(	NULL
hours	NULL
)	NULL
Fig	NULL
5	NULL
.	NULL

BCL-6	NULL
expression	NULL
after	NULL
stimulation	NULL
of	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Northern	NULL
blot	NULL
analysis	NULL
for	NULL
BCL-6	NULL
and	NULL
GAPDH	NULL
expression	NULL
using	NULL
total	NULL
RNA	NULL
from	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
cultured	NULL
for	NULL
the	NULL
indicated	NULL
durations	NULL
with	NULL
PHA	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Quantitation	NULL
of	NULL
the	NULL
BCL-6/GAPDH	NULL
ratio	NULL
from	NULL
the	NULL
Northern	NULL
blots	NULL
in	NULL
(	NULL
A	NULL
)	NULL
.	NULL

has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
membrane	NULL
proteins	NULL
that	NULL
are	NULL
normally	NULL
found	NULL
only	NULL
on	NULL
activated	NULL
B	NULL
lymphocytes	NULL
.	NULL
``	NULL

LMPI	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
activate	NULL
NF-kB	NULL
,	NULL
``	NULL
``	NULL
``	NULL
``	NULL
possibly	NULL
by	NULL
virtue	NULL
of	NULL
its	NULL
association	NULL
with	NULL
a	NULL
member	NULL
of	NULL
the	NULL
TRAF	NULL
protein	NULL
family	NULL
.	NULL
``	NULL

''	NULL
Transactivation	NULL
of	NULL
cellular	NULL
genes	NULL
in	NULL
LCLs	NULL
is	NULL
mediated	NULL
additionally	NULL
by	NULL
the	NULL
EBNA2	NULL
protein	NULL
that	NULL
activates	NULL
cellular	NULL
promoters	NULL
indirectly	NULL
via	NULL
a	NULL
protein-protein	NULL
interaction	NULL
with	NULL
the	NULL
J	NULL
,	NULL
signal	NULL
recognition	NULL
protein	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
Additional	NULL
evidence	NULL
of	NULL
regulated	NULL
expression	NULL
of	NULL
BCL-6	NULL
came	NULL
from	NULL
the	NULL
observation	NULL
that	NULL
anti-Ig	NULL
treatment	NULL
of	NULL
Akata	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cells	NULL
caused	NULL
BCL-6	NULL
mRNA	NULL
levels	NULL
to	NULL
decrease	NULL
.	NULL

Akata	NULL
cells	NULL
triggered	NULL
with	NULL
anti-Ig	NULL
antibodies	NULL
activate	NULL
the	NULL
latent	NULL
EBV	NULL
genome	NULL
and	NULL
partially	NULL
resemble	NULL
LCLs	NULL
in	NULL
that	NULL
they	NULL
begin	NULL
to	NULL
express	NULL
the	NULL
latent	NULL
membrane	NULL
protein	NULL
gene	NULL
products	NULL
,	NULL
LMP1	NULL
,	NULL
LMP2A	NULL
,	NULL
and	NULL
LMP2B	NULL
.	NULL
``	NULL

However	NULL
,	NULL
activated	NULL
Akata	NULL
cells	NULL
differ	NULL
from	NULL
LCLs	NULL
in	NULL
that	NULL
they	NULL
do	NULL
not	NULL
express	NULL
EBNA2	NULL
and	NULL
do	NULL
express	NULL
the	NULL
several	NULL
EBV	NULL
gene	NULL
products	NULL
that	NULL
initiate	NULL
a	NULL
lytic	NULL
viral	NULL
cycle	NULL
.	NULL
``	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
not	NULL
clear	NULL
at	NULL
present	NULL
whether	NULL
the	NULL
downregulation	NULL
of	NULL
BCL-6	NULL
in	NULL
LCLs	NULL
and	NULL
Akata	NULL
cells	NULL
proceeds	NULL
by	NULL
the	NULL
same	NULL
or	NULL
distinct	NULL
pathways	NULL
.	NULL

It	NULL
will	NULL
therefore	NULL
be	NULL
interesting	NULL
to	NULL
delineate	NULL
which	NULL
EBV	NULL
gene	NULL
products	NULL
modulate	NULL
BCL-6	NULL
expression	NULL
as	NULL
this	NULL
may	NULL
shed	NULL
light	NULL
on	NULL
the	NULL
signaling	NULL
pathways	NULL
that	NULL
converge	NULL
on	NULL
the	NULL
BCL-6	NULL
gene	NULL
.	NULL

The	NULL
stimuli	NULL
that	NULL
downregulated	NULL
BCL-6	NULL
in	NULL
lymphocytes	NULL
act	NULL
through	NULL
distinct	NULL
signaling	NULL
pathways	NULL
but	NULL
were	NULL
all	NULL
mitogenic	NULL
.	NULL

B	NULL
lymphocytes	NULL
stimulated	NULL
with	NULL
anti-IgM	NULL
,	NULL
anti-IgD	NULL
,	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
,	NULL
LPS	NULL
,	NULL
CD40	NULL
ligand	NULL
,	NULL
or	NULL
SAC	NULL
plus	NULL
IL-2	NULL
had	NULL
decreased	NULL
BCL-6	NULL
levels	NULL
,	NULL
as	NULL
did	NULL
T	NULL
lymphocytes	NULL
stimulated	NULL
with	NULL
PHA	NULL
.	NULL

Signals	NULL
induced	NULL
in	NULL
B	NULL
cells	NULL
by	NULL
treatment	NULL
with	NULL
anti-IgM	NULL
or	NULL
LPS	NULL
are	NULL
mechanistically	NULL
distinct	NULL
in	NULL
that	NULL
anti-IgM	NULL
triggering	NULL
engages	NULL
tyrosine	NULL
kinases	NULL
that	NULL
are	NULL
inhibited	NULL
by	NULL
her-bimycin	NULL
,	NULL
whereas	NULL
LPS	NULL
signaling	NULL
is	NULL
not	NULL
affected	NULL
by	NULL
this	NULL
drug	NULL
.	NULL

*	NULL
'	NULL
Nevertheless	NULL
,	NULL
anti-Ig	NULL
and	NULL
LPS-derived	NULL
signals	NULL
converge	NULL
on	NULL
common	NULL
pathways	NULL
such	NULL
as	NULL
activation	NULL
of	NULL
NF-kB	NULL
.	NULL
``	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BCL-6	NULL
EXPRESSION	NULL
DURING	NULL
B-CELL	NULL
ACTIVATION	NULL
A	NULL
C	NULL
8	NULL
m	NULL
%	NULL
f	NULL
&	NULL
O	NULL
0	NULL
8	NULL
£9	NULL
:	NULL
é	NULL
m	NULL
®	NULL
o	NULL
2	NULL
an	NULL
c	NULL
E	NULL
3	NULL
>	NULL
&	NULL
-	NULL
200	NULL
kD	NULL
p	NULL
f	NULL
-	NULL
97	NULL
kD	NULL
BCL-6	NULL
-	NULL
WD	NULL
._	NULL
.	NULL

a	NULL
-	NULL
69	NULL
kD	NULL
SP	NULL
1	NULL
-	NULL
wn	NULL
00	NULL
ae	NULL
**	NULL
wa	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
B	NULL
Northern	NULL
r-	NULL
OU	NULL
C	NULL
)	NULL
has	NULL
+	NULL
+	NULL
O	NULL
[	NULL
op	NULL
]	NULL
O	NULL
B	NULL
Cells	NULL
]	NULL
EX	NULL
S	NULL
2	NULL
$	NULL
o	NULL
$	NULL
0	NULL
$	NULL
0	NULL
CGO	NULL
C	NULL
O	NULL
C	NULL
(	NULL
D	NULL
BCL-6	NULL
-	NULL
_-_	NULL
GAPDH	NULL
-	NULL
®	NULL
%	NULL
_	NULL
ue	NULL
*~	NULL
_	NULL
wt	NULL
wae	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
The	NULL
signaling	NULL
pathways	NULL
that	NULL
are	NULL
engaged	NULL
on	NULL
treatment	NULL
of	NULL
B	NULL
cells	NULL
with	NULL
CD40	NULL
ligand	NULL
have	NULL
not	NULL
been	NULL
fully	NULL
elucidated	NULL
,	NULL
although	NULL
NF-kB	NULL
is	NULL
also	NULL
activated	NULL
.	NULL

****	NULL
Interestingly	NULL
,	NULL
both	NULL
CD40	NULL
and	NULL
LMP1	NULL
interact	NULL
with	NULL
a	NULL
newly	NULL
described	NULL
member	NULL
of	NULL
the	NULL
TRAF	NULL
family	NULL
of	NULL
putative	NULL
signal	NULL
transduction	NULL
proteins	NULL
.	NULL

``	NULL
``	NULL
*	NULL
``	NULL
**	NULL
Because	NULL
LMPI	NULL
is	NULL
expressed	NULL
in	NULL
LCLs	NULL
,	NULL
it	NULL
is	NULL
conceivable	NULL
that	NULL
this	NULL
protein	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
downregulating	NULL
BCL-6	NULL
in	NULL
LCLs	NULL
as	NULL
well	NULL
as	NULL
in	NULL
CD40	NULL
ligand-stimulated	NULL
cells	NULL
.	NULL

Finally	NULL
,	NULL
it	NULL
is	NULL
important	NULL
to	NULL
note	NULL
that	NULL
all	NULL
of	NULL
the	NULL
signals	NULL
that	NULL
caused	NULL
downmodulation	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
in	NULL
vitro	NULL
were	NULL
mitogenic	NULL
.	NULL

The	NULL
downmodulation	NULL
of	NULL
BCL-6	NULL
occurred	NULL
8	NULL
to	NULL
16	NULL
hours	NULL
after	NULL
5265	NULL
Fig	NULL
6	NULL
.	NULL

-	NULL
BCL-6	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
in	NULL
naive	NULL
and	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
BCL-6	NULL
and	NULL
Sp1	NULL
protein	NULL
expression	NULL
in	NULL
purified	NULL
human	NULL
peripheral	NULL
blood	NULL
B	NULL
cells	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
human	NULL
tonsillar	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
B-cell	NULL
lines	NULL
that	NULL
express	NULL
BCL-6	NULL
mRNA	NULL
(	NULL
BJAB	NULL
and	NULL
RL	NULL
;	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
or	NULL
do	NULL
not	NULL
express	NULL
BCL-6	NULL
mRNA	NULL
(	NULL
VDSO	NULL
;	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
and	NULL
in	NULL
vitro-translated	NULL
BCL-6	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
incubated	NULL
with	NULL
a	NULL
polyclonal	NULL
antibody	NULL
directed	NULL
against	NULL
the	NULL
amino-terminal	NULL
484	NULL
amino	NULL
acids	NULL
of	NULL
BCL-6	NULL
and	NULL
developed	NULL
using	NULL
an	NULL
ECL	NULL
kit	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Northern	NULL
and	NULL
Western	NULL
analysis	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
and	NULL
protein	NULL
in	NULL
purified	NULL
human	NULL
peripheral	NULL
blood	NULL
B	NULL
cells	NULL
(	NULL
Resting	NULL
#	NULL
1	NULL
through	NULL
3	NULL
)	NULL
and	NULL
human	NULL
tonsillar	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
(	NULL
GC	NULL
#	NULL
1	NULL
through	NULL
3	NULL
)	NULL
.	NULL

Each	NULL
sample	NULL
was	NULL
derived	NULL
from	NULL
a	NULL
different	NULL
human	NULL
donor	NULL
.	NULL

GAPDH	NULL
mRNA	NULL
expression	NULL
was	NULL
used	NULL
for	NULL
normalization	NULL
of	NULL
loading	NULL
on	NULL
the	NULL
Northern	NULL
blots	NULL
and	NULL
SP1	NULL
protein	NULL
expression	NULL
was	NULL
used	NULL
for	NULL
normalization	NULL
of	NULL
loading	NULL
on	NULL
the	NULL
Western	NULL
blots	NULL
.	NULL

Western	NULL
blots	NULL
were	NULL
incubated	NULL
with	NULL
an	NULL
antipeptide	NULL
antibody	NULL
specific	NULL
for	NULL
BCL-6	NULL
and	NULL
developed	NULL
using	NULL
radiolabeled	NULL
antirabbit	NULL
Ig	NULL
anti-bodies	NULL
.	NULL

Western	NULL
r-	NULL
OU	NULL
C	NULL
)	NULL
has	NULL
+	NULL
T	NULL
a	NULL
>	NULL
]	NULL
&	NULL
O	NULL
C	NULL
w	NULL
C	NULL
OU	NULL
|	NULL
end	NULL
C	NULL
)	NULL
13	NULL
%	NULL
3	NULL
%	NULL
f	NULL
3	NULL
o	NULL
O	NULL
o	NULL
-	NULL
O	NULL
o	NULL
-	NULL
O	NULL
C	NULL
(	NULL
5	NULL
C	NULL
G	NULL
C	NULL
(	NULL
5	NULL
BCL-6	NULL
-	NULL
_.	NULL
wane	NULL
|	NULL
Pare	NULL
__	NULL
3	NULL
soi	NULL
-	NULL
wees	NULL
-	NULL
Whe	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
stimulation	NULL
and	NULL
thus	NULL
was	NULL
not	NULL
an	NULL
immediate	NULL
early	NULL
event	NULL
.	NULL

Therefore	NULL
,	NULL
our	NULL
working	NULL
model	NULL
is	NULL
that	NULL
BCL-6	NULL
regulation	NULL
is	NULL
a	NULL
secondary	NULL
effect	NULL
of	NULL
in	NULL
vitro	NULL
mitogenic	NULL
signaling	NULL
that	NULL
is	NULL
mediated	NULL
indirectly	NULL
by	NULL
one	NULL
or	NULL
more	NULL
of	NULL
the	NULL
immediate	NULL
early	NULL
transcription	NULL
factors	NULL
.	NULL

However	NULL
,	NULL
a	NULL
striking	NULL
dichotomy	NULL
in	NULL
our	NULL
studies	NULL
is	NULL
that	NULL
,	NULL
although	NULL
in	NULL
vitro-activated	NULL
B	NULL
cells	NULL
have	NULL
low	NULL
BCL-6	NULL
mRNA	NULL
expression	NULL
,	NULL
activated	NULL
B	NULL
cells	NULL
from	NULL
human	NULL
germinal	NULL
centers	NULL
expressed	NULL
BCL-6	NULL
mRNA	NULL
to	NULL
the	NULL
same	NULL
degree	NULL
as	NULL
resting	NULL
B	NULL
lymphocytes	NULL
.	NULL

The	NULL
germinal	NULL
center	NULL
is	NULL
a	NULL
complex	NULL
microenvironment	NULL
in	NULL
which	NULL
T-cell-dependent	NULL
stimulation	NULL
of	NULL
B	NULL
lym-	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

5266	NULL
1	NULL
L	NULL
[	NULL
an	NULL
]	NULL
a_	NULL
<	NULL
Northern	NULL
_	NULL
3	NULL
<	NULL
P	NULL
Pik	NULL
O	NULL
[	NULL
aa	NULL
)	NULL
3	NULL
3	NULL
&	NULL
t	NULL
s	NULL
5	NULL
w	NULL
[	NULL
o	NULL
CC	NULL
15	NULL
53	NULL
107	NULL
Western	NULL
_	NULL
a	NULL
d	NULL
m	NULL
53	NULL
3p	NULL
&	NULL
(	NULL
6	NULL
)	NULL
C	NULL
(	NULL
5	NULL
&	NULL
O	NULL
C	NULL
Fig	NULL
6.	NULL
phocytes	NULL
leads	NULL
to	NULL
somatic	NULL
hypermutation	NULL
of	NULL
Ig	NULL
genes	NULL
,	NULL
Ig	NULL
isotype	NULL
class	NULL
switching	NULL
,	NULL
and	NULL
the	NULL
generation	NULL
of	NULL
memory	NULL
B	NULL
cells	NULL
and	NULL
plasma	NULL
cells	NULL
.	NULL
``	NULL

Activation	NULL
of	NULL
B	NULL
cells	NULL
in	NULL
germinal	NULL
centers	NULL
results	NULL
from	NULL
the	NULL
interplay	NULL
of	NULL
three	NULL
cell	NULL
types	NULL
:	NULL
antigen-specific	NULL
B	NULL
cells	NULL
,	NULL
antigen-specific	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
follicular	NULL
dendritic	NULL
cells	NULL
.	NULL

Activated	NULL
T	NULL
cells	NULL
display	NULL
CD40	NULL
ligand	NULL
on	NULL
their	NULL
cell	NULL
surface	NULL
and	NULL
stimulate	NULL
B	NULL
cells	NULL
through	NULL
CD40	NULL
.	NULL

Indeed	NULL
,	NULL
ongoing	NULL
CD40	NULL
signaling	NULL
is	NULL
necessary	NULL
to	NULL
maintain	NULL
the	NULL
germinal	NULL
center	NULL
response	NULL
.	NULL
``	NULL

Interactions	NULL
between	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
germinal	NULL
center	NULL
also	NULL
include	NULL
binding	NULL
of	NULL
B7-2	NULL
on	NULL
the	NULL
B-cell	NULL
surface	NULL
to	NULL
CD28/CTLA-4	NULL
on	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
this	NULL
signaling	NULL
event	NULL
is	NULL
important	NULL
for	NULL
the	NULL
generation	NULL
of	NULL
B-cell	NULL
memory	NULL
and	NULL
somatic	NULL
hypermutation	NULL
of	NULL
Ig	NULL
genes	NULL
.	NULL
``	NULL

Antigen	NULL
present	NULL
as	NULL
immune	NULL
complexes	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
follicular	NULL
dendritic	NULL
cells	NULL
may	NULL
signal	NULL
B	NULL
cells	NULL
through	NULL
their	NULL
cell	NULL
surface	NULL
receptor	NULL
.	NULL
``	NULL

Finally	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
soluble	NULL
antigen	NULL
can	NULL
signal	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
through	NULL
the	NULL
cell	NULL
surface	NULL
Ig	NULL
receptor	NULL
to	NULL
undergo	NULL
apoptosis	NULL
.	NULL
``	NULL

''	NULL
``	NULL
'	NULL
Thus	NULL
,	NULL
the	NULL
signaling	NULL
of	NULL
B	NULL
cells	NULL
in	NULL
ALLMAN	NULL
ET	NULL
AL	NULL
0.25	NULL
0.2	NULL
Resting	NULL
#	NULL
2	NULL
GC	NULL
#	NULL
2	NULL
Resting	NULL
#	NULL
3	NULL
GC	NULL
#	NULL
3	NULL
GC	NULL
#	NULL
2	NULL
GC	NULL
#	NULL
3	NULL
o	NULL
o	NULL
#	NULL
4	NULL
&	NULL
&	NULL
-S	NULL
-S	NULL
t	NULL
o	NULL
0	NULL
0	NULL
tL	NULL
CC	NULL
(	NULL
cont	NULL
'd	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Quantitative	NULL
analysis	NULL
of	NULL
the	NULL
Northern	NULL
and	NULL
Western	NULL
blot	NULL
data	NULL
in	NULL
(	NULL
B	NULL
)	NULL
using	NULL
a	NULL
Phosphorimager	NULL
.	NULL

germinal	NULL
centers	NULL
is	NULL
multifactorial	NULL
and	NULL
not	NULL
readily	NULL
mimicked	NULL
within	NULL
in	NULL
vitro	NULL
cultures	NULL
.	NULL

Indeed	NULL
,	NULL
B	NULL
cells	NULL
stimulated	NULL
in	NULL
vitro	NULL
through	NULL
CD40	NULL
along	NULL
with	NULL
interleukin-4	NULL
are	NULL
able	NULL
to	NULL
switch	NULL
Ig	NULL
isotype	NULL
but	NULL
do	NULL
not	NULL
allow	NULL
somatic	NULL
hypermutation	NULL
of	NULL
Ig	NULL
genes	NULL
.	NULL
``	NULL

In	NULL
light	NULL
of	NULL
the	NULL
complex	NULL
nature	NULL
of	NULL
the	NULL
germinal	NULL
center	NULL
micro-environment	NULL
,	NULL
it	NULL
is	NULL
less	NULL
surprising	NULL
that	NULL
BCL-6	NULL
mRNA	NULL
expression	NULL
differed	NULL
between	NULL
B	NULL
cells	NULL
activated	NULL
in	NULL
vitro	NULL
and	NULL
B	NULL
cells	NULL
activated	NULL
in	NULL
germinal	NULL
centers	NULL
.	NULL

Clearly	NULL
,	NULL
our	NULL
in	NULL
vitro	NULL
culture	NULL
conditions	NULL
must	NULL
lack	NULL
critical	NULL
coordinate	NULL
signals	NULL
that	NULL
are	NULL
present	NULL
within	NULL
the	NULL
germinal	NULL
center	NULL
and	NULL
serve	NULL
to	NULL
maintain	NULL
BCL6	NULL
mRNA	NULL
expression	NULL
during	NULL
B-cell	NULL
activation	NULL
.	NULL

Quantitative	NULL
analysis	NULL
of	NULL
BCL-6	NULL
protein	NULL
levels	NULL
revealed	NULL
that	NULL
purified	NULL
human	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
expressed	NULL
considerably	NULL
more	NULL
protein	NULL
than	NULL
resting	NULL
human	NULL
B	NULL
cells	NULL
purified	NULL
from	NULL
peripheral	NULL
blood	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
in	NULL
keeping	NULL
with	NULL
recent	NULL
immunohistochemical	NULL
studies	NULL
of	NULL
human	NULL
lymphoid	NULL
tissues	NULL
that	NULL
showed	NULL
that	NULL
BCL-6	NULL
protein	NULL
was	NULL
readily	NULL
detectable	NULL
in	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
most	NULL
resting	NULL
B	NULL
cells	NULL
in	NULL
the	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BCL-6	NULL
EXPRESSION	NULL
DURING	NULL
B-CELL	NULL
ACTIVATION	NULL
mantle	NULL
and	NULL
marginal	NULL
zones	NULL
.	NULL
``	NULL

However	NULL
,	NULL
an	NULL
unanticipated	NULL
finding	NULL
was	NULL
that	NULL
the	NULL
higher	NULL
BCL-6	NULL
protein	NULL
levels	NULL
in	NULL
germinal	NULL
center	NULL
cells	NULL
could	NULL
not	NULL
be	NULL
fully	NULL
accounted	NULL
for	NULL
by	NULL
increased	NULL
mRNA	NULL
expression	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
some	NULL
preparations	NULL
of	NULL
resting	NULL
and	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
,	NULL
BCL-6	NULL
protein	NULL
levels	NULL
were	NULL
threefold	NULL
to	NULL
34-fold	NULL
higher	NULL
in	NULL
the	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
despite	NULL
roughly	NULL
comparable	NULL
BCL-6	NULL
mRNA	NULL
levels	NULL
in	NULL
the	NULL
two	NULL
cell	NULL
populations	NULL
.	NULL

These	NULL
data	NULL
raise	NULL
the	NULL
possibility	NULL
that	NULL
regulation	NULL
of	NULL
mRNA	NULL
levels	NULL
may	NULL
not	NULL
be	NULL
the	NULL
only	NULL
mechanism	NULL
by	NULL
which	NULL
BCL-6	NULL
protein	NULL
expression	NULL
is	NULL
upregulated	NULL
in	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
.	NULL

mRNA	NULL
translation	NULL
is	NULL
regulated	NULL
in	NULL
many	NULL
genes	NULL
and	NULL
can	NULL
be	NULL
mediated	NULL
by	NULL
binding	NULL
of	NULL
proteins	NULL
to	NULL
cis-acting	NULL
RNA	NULL
motifs	NULL
in	NULL
the	NULL
untranslated	NULL
regions	NULL
of	NULL
mRNAs	NULL
.	NULL
``	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
it	NULL
is	NULL
interesting	NULL
that	NULL
the	NULL
untranslated	NULL
regions	NULL
of	NULL
human	NULL
and	NULL
mouse	NULL
BCL-6	NULL
mRNA	NULL
have	NULL
stretches	NULL
of	NULL
high	NULL
sequence	NULL
conservation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Posttranslational	NULL
protein	NULL
modifications	NULL
can	NULL
affect	NULL
steady-state	NULL
protein	NULL
levels	NULL
by	NULL
altering	NULL
protein	NULL
stability	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
noteworthy	NULL
that	NULL
BCL-6	NULL
is	NULL
a	NULL
phosphoprotein	NULL
,	NULL
``	NULL
because	NULL
protein	NULL
phosphoylation	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
alter	NULL
the	NULL
rate	NULL
of	NULL
degradation	NULL
of	NULL
some	NULL
pro-teins	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
Future	NULL
analysis	NULL
of	NULL
BCL-6	NULL
mutants	NULL
should	NULL
show	NULL
whether	NULL
translational	NULL
and	NULL
posttranslational	NULL
mechanisms	NULL
govern	NULL
the	NULL
regulation	NULL
of	NULL
BCL-6	NULL
protein	NULL
expression	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
two	NULL
modes	NULL
of	NULL
regulation	NULL
are	NULL
used	NULL
to	NULL
ensure	NULL
high-level	NULL
BCL-6	NULL
protein	NULL
expression	NULL
in	NULL
germinal	NULL
centers	NULL
.	NULL

First	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
many	NULL
modes	NULL
of	NULL
B	NULL
cell	NULL
activation	NULL
in	NULL
vitro	NULL
,	NULL
B-cell	NULL
activation	NULL
in	NULL
germinal	NULL
centers	NULL
does	NULL
not	NULL
lead	NULL
to	NULL
the	NULL
downmodulation	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
expression	NULL
.	NULL

Second	NULL
,	NULL
our	NULL
data	NULL
suggest	NULL
that	NULL
BCL-6	NULL
protein	NULL
levels	NULL
may	NULL
be	NULL
regulated	NULL
independently	NULL
of	NULL
BCL-6	NULL
mRNA	NULL
levels	NULL
,	NULL
resulting	NULL
in	NULL
higher	NULL
BCL-6	NULL
protein	NULL
levels	NULL
in	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
than	NULL
in	NULL
resting	NULL
B	NULL
cells	NULL
.	NULL

Such	NULL
complex	NULL
regulation	NULL
of	NULL
BCL-6	NULL
expression	NULL
during	NULL
B-cell	NULL
activation	NULL
is	NULL
consistent	NULL
with	NULL
a	NULL
postulated	NULL
im-	NULL
portant	NULL
and	NULL
selective	NULL
function	NULL
of	NULL
BCL-6	NULL
during	NULL
the	NULL
germinal	NULL
center	NULL
reaction	NULL
.	NULL

ACKNOWLEDGMENT	NULL
The	NULL
authors	NULL
thank	NULL
Dr	NULL
Li	NULL
Yin	NULL
for	NULL
preparing	NULL
RNA	NULL
from	NULL
stimulated	NULL
T	NULL
cells	NULL
;	NULL
Dr	NULL
Jeff	NULL
Cohen	NULL
for	NULL
Akata	NULL
,	NULL
LCL-2	NULL
,	NULL
and	NULL
LCL-4	NULL
cells	NULL
and	NULL
advice	NULL
concerning	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
;	NULL
and	NULL
Dr	NULL
Warren	NULL
Strober	NULL
for	NULL
helpful	NULL
discussions	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Baron	NULL
BW	NULL
,	NULL
Nucifora	NULL
G	NULL
,	NULL
McCabe	NULL
N	NULL
,	NULL
Espinosa	NULL
RI	NULL
,	NULL
LeBeau	NULL
MM	NULL
,	NULL
McKeithan	NULL
TW	NULL
:	NULL
Identification	NULL
of	NULL
the	NULL
gene	NULL
associated	NULL
with	NULL
the	NULL
recurring	NULL
chromosomal	NULL
translocations	NULL
t	NULL
(	NULL
3	NULL
;	NULL
14	NULL
)	NULL
(	NULL
q27	NULL
;	NULL
q23	NULL
)	NULL
and	NULL
t	NULL
(	NULL
3	NULL
;	NULL
22	NULL
)	NULL
(	NULL
q27	NULL
;	NULL
q11	NULL
)	NULL
in	NULL
B-cell	NULL
lymphomas	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
90:5262	NULL
,	NULL
1993	NULL
2	NULL
.	NULL

Miki	NULL
T	NULL
,	NULL
Kawamata	NULL
N	NULL
,	NULL
Hirosawa	NULL
S	NULL
,	NULL
Aoki	NULL
N	NULL
:	NULL
Gene	NULL
involved	NULL
in	NULL
the	NULL
3q27	NULL
translocation	NULL
associated	NULL
with	NULL
B-cell	NULL
lymphoma	NULL
,	NULL
BCLS5	NULL
,	NULL
encodes	NULL
a	NULL
kriippel-like	NULL
zinc-finger	NULL
protein	NULL
.	NULL

Blood	NULL
83:26	NULL
,	NULL
1994	NULL
3	NULL
.	NULL

Ye	NULL
BH	NULL
,	NULL
Lista	NULL
F	NULL
,	NULL
Lo	NULL
Coco	NULL
F	NULL
,	NULL
Knowles	NULL
DM	NULL
,	NULL
Offit	NULL
K	NULL
,	NULL
Chaganti	NULL
RSK	NULL
,	NULL
Dalla-Favera	NULL
R	NULL
:	NULL
Alterations	NULL
of	NULL
a	NULL
zinc	NULL
finger-encoding	NULL
gene	NULL
,	NULL
BCL-6	NULL
,	NULL
in	NULL
diffuse	NULL
large-cell	NULL
lymphoma	NULL
.	NULL

Science	NULL
262:747	NULL
,	NULL
1993	NULL
4	NULL
.	NULL

Kerckaert	NULL
JP	NULL
,	NULL
Deweindt	NULL
C	NULL
,	NULL
Tilly	NULL
H	NULL
,	NULL
Quief	NULL
S	NULL
,	NULL
Lecocq	NULL
G	NULL
,	NULL
Bastard	NULL
C	NULL
:	NULL
LAZ3	NULL
,	NULL
a	NULL
novel	NULL
zinc-finger	NULL
encoding	NULL
gene	NULL
,	NULL
is	NULL
disrupted	NULL
by	NULL
recurring	NULL
chromosome	NULL
3q27	NULL
translocations	NULL
in	NULL
human	NULL
lymphomas	NULL
.	NULL

Nat	NULL
Genet	NULL
5:66	NULL
,	NULL
1993	NULL
5	NULL
.	NULL

Magrath	NULL
IT	NULL
:	NULL
The	NULL
Non-Hodgkin	NULL
's	NULL
lymphomas	NULL
:	NULL
an	NULL
introduction	NULL
,	NULL
in	NULL
Magrath	NULL
IT	NULL
(	NULL
ed	NULL
)	NULL
:	NULL
The	NULL
Non-Hodgkin	NULL
's	NULL
Lymphomas	NULL
.	NULL

London	NULL
,	NULL
UK	NULL
,	NULL
Arnold	NULL
,	NULL
1990	NULL
,	NULL
p	NULL
1	NULL
5267	NULL
6	NULL
.	NULL

LoCoco	NULL
F	NULL
,	NULL
Ye	NULL
BH	NULL
,	NULL
Lista	NULL
F	NULL
,	NULL
Corradini	NULL
P	NULL
,	NULL
Offit	NULL
K	NULL
,	NULL
Knowles	NULL
DM	NULL
,	NULL
Chaganti	NULL
RSK	NULL
,	NULL
Dalla-Favera	NULL
R	NULL
:	NULL
Rearrangements	NULL
of	NULL
the	NULL
BCL6	NULL
gene	NULL
in	NULL
diffuse	NULL
large	NULL
cell	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
.	NULL

Blood	NULL
83:1757	NULL
,	NULL
1994	NULL
7	NULL
.	NULL

Bastard	NULL
C	NULL
,	NULL
Deweindt	NULL
C	NULL
,	NULL
Kerckaert	NULL
JP	NULL
,	NULL
Lenormand	NULL
B	NULL
,	NULL
Rossi	NULL
A	NULL
,	NULL
Peagella	NULL
F	NULL
,	NULL
Fruchart	NULL
C	NULL
,	NULL
Duval	NULL
C	NULL
,	NULL
Monconduit	NULL
M	NULL
,	NULL
Tilly	NULL
H	NULL
:	NULL
LAZ3	NULL
rearrangements	NULL
in	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
:	NULL
Correlation	NULL
with	NULL
his-tology	NULL
,	NULL
immunophenotype	NULL
,	NULL
karyotype	NULL
,	NULL
and	NULL
clinical	NULL
outcome	NULL
in	NULL
217	NULL
patients	NULL
.	NULL

Blood	NULL
83:2423	NULL
,	NULL
1994	NULL
8	NULL
.	NULL

Otsuki	NULL
T	NULL
,	NULL
Yano	NULL
T	NULL
,	NULL
Clark	NULL
HM	NULL
,	NULL
Bastard	NULL
C	NULL
,	NULL
Kerckaert	NULL
JP	NULL
,	NULL
Jaffe	NULL
ES	NULL
,	NULL
Raffeld	NULL
M	NULL
:	NULL
Analysis	NULL
of	NULL
LAZ3	NULL
(	NULL
BCL-6	NULL
)	NULL
status	NULL
in	NULL
B-cell	NULL
non-Hodgkin	NULL
's	NULL
lymphomas	NULL
:	NULL
Results	NULL
of	NULL
rearrangement	NULL
and	NULL
gene	NULL
expression	NULL
studies	NULL
and	NULL
a	NULL
mutational	NULL
analysis	NULL
of	NULL
coding	NULL
region	NULL
sequences	NULL
.	NULL

Blood	NULL
85:2877	NULL
,	NULL
1995	NULL
9	NULL
.	NULL

Gaidano	NULL
G	NULL
,	NULL
LoCoco	NULL
F	NULL
,	NULL
Ye	NULL
BH	NULL
,	NULL
Shibata	NULL
D	NULL
,	NULL
Levine	NULL
AM	NULL
,	NULL
Knowles	NULL
DM	NULL
,	NULL
Dalla-Favera	NULL
R	NULL
:	NULL
Rearrangements	NULL
of	NULL
the	NULL
BCL-6	NULL
gene	NULL
in	NULL
acquired	NULL
immunodeficiency	NULL
syndrome-associated	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
:	NULL
Association	NULL
with	NULL
diffuse	NULL
large-cell	NULL
subtype	NULL
.	NULL

Blood	NULL
84:397	NULL
,	NULL
1994	NULL
10	NULL
.	NULL

Offit	NULL
K	NULL
,	NULL
LoCoco	NULL
F	NULL
,	NULL
Louie	NULL
DC	NULL
,	NULL
Parsa	NULL
NZ	NULL
,	NULL
Leung	NULL
D	NULL
,	NULL
Portlock	NULL
C	NULL
,	NULL
Ye	NULL
BH	NULL
,	NULL
Lista	NULL
F	NULL
,	NULL
Filippa	NULL
DA	NULL
,	NULL
Rosenbaum	NULL
A	NULL
,	NULL
Ladanyi	NULL
M	NULL
,	NULL
Jbanwar	NULL
S	NULL
,	NULL
Dalla-Favera	NULL
R	NULL
,	NULL
Chaganti	NULL
RSK	NULL
:	NULL
Rearrangement	NULL
of	NULL
the	NULL
bel-6	NULL
gene	NULL
as	NULL
a	NULL
prognostic	NULL
marker	NULL
in	NULL
diffuse	NULL
large-cell	NULL
lymphoma	NULL
.	NULL

N	NULL
Engl	NULL
J	NULL
Med	NULL
331:74	NULL
,	NULL
1994	NULL
11	NULL
.	NULL

Bardwell	NULL
VJ	NULL
,	NULL
Treisman	NULL
R	NULL
:	NULL
The	NULL
POZ	NULL
domain	NULL
:	NULL
A	NULL
conserved	NULL
protein-protein	NULL
interaction	NULL
motif	NULL
.	NULL

Genes	NULL
Dev	NULL
8:1664	NULL
,	NULL
1994	NULL
12	NULL
.	NULL

Cattoretti	NULL
G	NULL
,	NULL
Chang	NULL
C-C	NULL
,	NULL
Cechova	NULL
K	NULL
,	NULL
Zhang	NULL
J	NULL
,	NULL
Ye	NULL
BH	NULL
,	NULL
Falini	NULL
B	NULL
,	NULL
Louie	NULL
DC	NULL
,	NULL
Offit	NULL
K	NULL
,	NULL
Chaganti	NULL
RSK	NULL
,	NULL
Dalla-Favera	NULL
R	NULL
:	NULL
Bcl-6	NULL
protein	NULL
is	NULL
expressed	NULL
in	NULL
germinal-center	NULL
B	NULL
cells	NULL
.	NULL

Blood	NULL
86:45	NULL
,	NULL
1995	NULL
13	NULL
.	NULL

Onizuka	NULL
T	NULL
,	NULL
MMoriyama	NULL
M	NULL
,	NULL
Yamochi	NULL
T	NULL
,	NULL
Kuroda	NULL
T	NULL
,	NULL
Kazama	NULL
A	NULL
,	NULL
Kanazawa	NULL
N	NULL
,	NULL
Sato	NULL
K	NULL
,	NULL
Kato	NULL
T	NULL
,	NULL
Ota	NULL
H	NULL
,	NULL
Mori	NULL
S	NULL
:	NULL
Bel-6	NULL
gene	NULL
product	NULL
,	NULL
a	NULL
92-	NULL
to	NULL
I8kD	NULL
nuclear	NULL
phosphoprotein	NULL
,	NULL
is	NULL
highly	NULL
expressed	NULL
in	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
and	NULL
their	NULL
neoplastic	NULL
counterparts	NULL
.	NULL

Blood	NULL
86:28	NULL
,	NULL
1995	NULL
14	NULL
.	NULL

Flenghi	NULL
L	NULL
,	NULL
Ye	NULL
BH	NULL
,	NULL
Fizzotti	NULL
M	NULL
,	NULL
Bigema	NULL
B	NULL
,	NULL
Cattoretti	NULL
G	NULL
,	NULL
Ven-turi	NULL
S	NULL
,	NULL
Pacini	NULL
R	NULL
,	NULL
Pileri	NULL
S	NULL
,	NULL
Lo	NULL
Coco	NULL
F	NULL
,	NULL
Pescarmona	NULL
E	NULL
,	NULL
Pelicci	NULL
P-G	NULL
,	NULL
Dalla-Favera	NULL
R	NULL
,	NULL
Falini	NULL
B	NULL
:	NULL
A	NULL
specific	NULL
monoclonal	NULL
antibody	NULL
(	NULL
PG-B6	NULL
)	NULL
detects	NULL
expression	NULL
of	NULL
the	NULL
BCL-6	NULL
protein	NULL
in	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
.	NULL

Am	NULL
J	NULL
Pathol	NULL
147:405	NULL
,	NULL
1995	NULL
15	NULL
.	NULL

Staudt	NULL
LM	NULL
,	NULL
Dent	NULL
A	NULL
,	NULL
Ma	NULL
C	NULL
,	NULL
Allman	NULL
D	NULL
,	NULL
Powell	NULL
J	NULL
,	NULL
Maile	NULL
R	NULL
,	NULL
Scherle	NULL
P	NULL
,	NULL
Behrens	NULL
T	NULL
:	NULL
Rapid	NULL
indentification	NULL
of	NULL
novel	NULL
human	NULL
lymphoid-restricted	NULL
genes	NULL
by	NULL
automated	NULL
DNA	NULL
sequencing	NULL
of	NULL
subtracted	NULL
cDNA	NULL
libraries	NULL
.	NULL

Curr	NULL
Top	NULL
Microbiol	NULL
Immunol	NULL
194	NULL
;	NULL
:155	NULL
,	NULL
1994	NULL
16	NULL
.	NULL

Allman	NULL
DM	NULL
,	NULL
Ferguson	NULL
SE	NULL
,	NULL
Cancro	NULL
MP	NULL
:	NULL
Peripheral	NULL
B	NULL
cell	NULL
maturation	NULL
I.	NULL
Immature	NULL
peripheral	NULL
B	NULL
cells	NULL
are	NULL
heat-stable	NULL
antigen	NULL
``	NULL
and	NULL
exhibit	NULL
unique	NULL
signaling	NULL
properties	NULL
.	NULL

J	NULL
Immunol	NULL
149:2533	NULL
,	NULL
1992	NULL
17	NULL
.	NULL

Funderud	NULL
S	NULL
,	NULL
Erikstein	NULL
B	NULL
,	NULL
Asheim	NULL
HC	NULL
,	NULL
Nustad	NULL
K	NULL
,	NULL
Stokke	NULL
T	NULL
,	NULL
Biomhoff	NULL
HK	NULL
,	NULL
Holte	NULL
H	NULL
,	NULL
Smeland	NULL
EB	NULL
:	NULL
Functional	NULL
properties	NULL
of	NULL
CD19+	NULL
B	NULL
lymphocytes	NULL
positively	NULL
selected	NULL
from	NULL
buffy	NULL
coats	NULL
by	NULL
im-munomagnetic	NULL
separation	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
20:201	NULL
,	NULL
1990	NULL
18	NULL
.	NULL

Liu	NULL
Y-J	NULL
,	NULL
Banchereau	NULL
J	NULL
;	NULL
Human	NULL
peripheral	NULL
B	NULL
cell	NULL
subsets	NULL
,	NULL
in	NULL
Weir	NULL
D	NULL
,	NULL
Blackwell	NULL
C	NULL
,	NULL
Herzenberg	NULL
L	NULL
,	NULL
Herzenberg	NULL
L	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
Handbook	NULL
of	NULL
Expimental	NULL
Immunology	NULL
(	NULL
ed	NULL
5	NULL
)	NULL
.	NULL

Oxford	NULL
,	NULL
UK	NULL
,	NULL
Blackwell	NULL
Scientific	NULL
(	NULL
in	NULL
press	NULL
)	NULL
19	NULL
.	NULL

Irving	NULL
SG	NULL
,	NULL
June	NULL
CH	NULL
,	NULL
Zipfel	NULL
PF	NULL
,	NULL
Siebenlist	NULL
U	NULL
,	NULL
Kelly	NULL
K	NULL
:	NULL
Mito-gen-induced	NULL
genes	NULL
are	NULL
subject	NULL
to	NULL
multiple	NULL
pathways	NULL
of	NULL
regulation	NULL
in	NULL
the	NULL
initial	NULL
stages	NULL
of	NULL
T-cell	NULL
activation	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
9:1034	NULL
,	NULL
1989	NULL
20	NULL
.	NULL

Seyfert	NULL
VL	NULL
,	NULL
McMahon	NULL
S	NULL
,	NULL
Glenn	NULL
W	NULL
,	NULL
Cao	NULL
X	NULL
,	NULL
Sukhatme	NULL
VP	NULL
,	NULL
Monroe	NULL
JG	NULL
:	NULL
Egr-1	NULL
expression	NULL
in	NULL
surface	NULL
Ig-mediated	NULL
B	NULL
cell	NULL
activation	NULL
.	NULL

Kinetics	NULL
and	NULL
association	NULL
with	NULL
protein	NULL
kinase	NULL
C	NULL
activation	NULL
.	NULL

J	NULL
Immunol	NULL
145:3647	NULL
,	NULL
1990	NULL
21	NULL
.	NULL

Coligan	NULL
JE	NULL
,	NULL
Kruisbeeck	NULL
AM	NULL
,	NULL
Margulies	NULL
DH	NULL
,	NULL
Shevach	NULL
EM	NULL
,	NULL
Strober	NULL
W	NULL
:	NULL
Current	NULL
Protocols	NULL
in	NULL
Immunology	NULL
,	NULL
vol	NULL
1	NULL
.	NULL

New	NULL
York	NULL
,	NULL
Green	NULL
Publishing	NULL
and	NULL
Wiley-Interscience	NULL
,	NULL
1993	NULL
22	NULL
.	NULL

Jumper	NULL
MD	NULL
,	NULL
Nishioka	NULL
Y	NULL
,	NULL
Davis	NULL
LS	NULL
,	NULL
Lipsky	NULL
PE	NULL
,	NULL
Meek	NULL
K	NULL
:	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

5268	NULL
Regulation	NULL
of	NULL
human	NULL
B	NULL
cell	NULL
function	NULL
by	NULL
recombinant	NULL
CD40	NULL
ligand	NULL
and	NULL
other	NULL
TNF-related	NULL
ligands	NULL
.	NULL

J	NULL
Immunol	NULL
155:2369	NULL
,	NULL
1995	NULL
23	NULL
.	NULL

O'Reilly	NULL
DR	NULL
,	NULL
Miller	NULL
LK	NULL
,	NULL
Luckow	NULL
VA	NULL
:	NULL
Baculovirus	NULL
expression	NULL
vectors	NULL
,	NULL
a	NULL
laboratory	NULL
manual	NULL
.	NULL

New	NULL
York	NULL
,	NULL
NY	NULL
,	NULL
Freeman	NULL
,	NULL
1992	NULL
24	NULL
.	NULL

Kehry	NULL
MR	NULL
,	NULL
Castle	NULL
BE	NULL
:	NULL
Regulation	NULL
of	NULL
CD40	NULL
ligand	NULL
expression	NULL
and	NULL
use	NULL
of	NULL
recombinant	NULL
CD40	NULL
ligand	NULL
for	NULL
studying	NULL
B	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
.	NULL

Semin	NULL
Immunol	NULL
6:287	NULL
,	NULL
1994	NULL
25	NULL
.	NULL

Hodgkin	NULL
PD	NULL
,	NULL
Yamashita	NULL
LC	NULL
,	NULL
Coffman	NULL
RL	NULL
,	NULL
Kehry	NULL
MR	NULL
:	NULL
Separation	NULL
of	NULL
events	NULL
mediating	NULL
B	NULL
cell	NULL
proliferation	NULL
and	NULL
Ig	NULL
production	NULL
by	NULL
using	NULL
T	NULL
cell	NULL
membranes	NULL
and	NULL
lymphokines	NULL
.	NULL

J	NULL
Immunol	NULL
145:2025	NULL
,	NULL
1990	NULL
26	NULL
.	NULL

Sambrook	NULL
J	NULL
,	NULL
Fritsch	NULL
EF	NULL
,	NULL
Maniatis	NULL
T	NULL
:	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
1989	NULL
27	NULL
.	NULL

Fort	NULL
P	NULL
,	NULL
Marty	NULL
L	NULL
,	NULL
Piechaczyk	NULL
M	NULL
,	NULL
Sabrouty	NULL
SE	NULL
,	NULL
Dani	NULL
C	NULL
,	NULL
Jean-teur	NULL
P	NULL
,	NULL
Blanchard	NULL
JM	NULL
:	NULL
Various	NULL
rat	NULL
adult	NULL
tissues	NULL
express	NULL
only	NULL
one	NULL
major	NULL
mRNA	NULL
species	NULL
from	NULL
the	NULL
glyceraldehyde-3-phosphate-dehy-drogenase	NULL
multigenic	NULL
family	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
13:1431	NULL
,	NULL
1985	NULL
28	NULL
.	NULL

Miki	NULL
T	NULL
,	NULL
Kawamata	NULL
N	NULL
,	NULL
Arai	NULL
A	NULL
,	NULL
Ohashi	NULL
K	NULL
,	NULL
Nakamura	NULL
Y	NULL
,	NULL
Kato	NULL
A	NULL
,	NULL
Hirosawa	NULL
S	NULL
,	NULL
Aoki	NULL
N	NULL
:	NULL
Molecular	NULL
cloning	NULL
of	NULL
the	NULL
breakpoint	NULL
for	NULL
3q27	NULL
translocation	NULL
in	NULL
B-cell	NULL
lymphomas	NULL
and	NULL
leukemias	NULL
.	NULL

Blood	NULL
83:217	NULL
,	NULL
1994	NULL
29	NULL
.	NULL

Calender	NULL
A	NULL
,	NULL
Billaud	NULL
M	NULL
,	NULL
Aubry	NULL
JP	NULL
,	NULL
Banchereau	NULL
J	NULL
,	NULL
Vuillaume	NULL
M	NULL
,	NULL
Lenoir	NULL
GM	NULL
:	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
induces	NULL
expression	NULL
of	NULL
B-cell	NULL
activation	NULL
markers	NULL
on	NULL
in	NULL
vitro	NULL
infection	NULL
of	NULL
EBV-negative	NULL
B-lymphoma	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
8	NULL
$	NULL
4:8060	NULL
,	NULL
1987	NULL
30	NULL
.	NULL

Wang	NULL
F	NULL
,	NULL
Gregory	NULL
CD	NULL
,	NULL
Rowe	NULL
M	NULL
,	NULL
Rickinson	NULL
AB	NULL
,	NULL
Wang	NULL
D	NULL
,	NULL
Birkenbach	NULL
M	NULL
,	NULL
Kikutani	NULL
H	NULL
,	NULL
Kishimoto	NULL
T	NULL
,	NULL
Kieff	NULL
E	NULL
:	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2	NULL
specifically	NULL
induces	NULL
expression	NULL
of	NULL
the	NULL
B-cell	NULL
activation	NULL
antigen	NULL
CD23	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
84:3452	NULL
,	NULL
1987	NULL
31	NULL
.	NULL

Wang	NULL
D	NULL
,	NULL
Liebowitz	NULL
D	NULL
,	NULL
Wang	NULL
F	NULL
,	NULL
Gregory	NULL
C	NULL
,	NULL
Rickinson	NULL
A	NULL
,	NULL
Larson	NULL
R	NULL
,	NULL
Springer	NULL
T	NULL
,	NULL
Kieff	NULL
E	NULL
:	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
infection	NULL
membrane	NULL
protein	NULL
alters	NULL
the	NULL
human	NULL
B-lymphocyte	NULL
phenotype	NULL
:	NULL
deletion	NULL
of	NULL
the	NULL
amino	NULL
terminus	NULL
abolishes	NULL
activity	NULL
.	NULL

J	NULL
Virol	NULL
62:4173	NULL
,	NULL
1988	NULL
32	NULL
.	NULL

Rowe	NULL
M	NULL
,	NULL
Lear	NULL
AL	NULL
,	NULL
Croom-Carter	NULL
D	NULL
,	NULL
Davies	NULL
AH	NULL
,	NULL
Rickinson	NULL
AB	NULL
:	NULL
Three	NULL
pathways	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
gene	NULL
activation	NULL
from	NULL
EBNA	NULL
!	NULL

-positive	NULL
latency	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

J	NULL
Virol	NULL
66:122	NULL
,	NULL
1992	NULL
33	NULL
.	NULL

Schittek	NULL
B	NULL
,	NULL
Rajewsky	NULL
K	NULL
,	NULL
Forster	NULL
I	NULL
:	NULL
Dividing	NULL
cells	NULL
in	NULL
bone	NULL
marrow	NULL
and	NULL
spleen	NULL
incorporate	NULL
bromodeoxyuridine	NULL
with	NULL
high	NULL
effi-ciency	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
21:235	NULL
,	NULL
1991	NULL
34	NULL
.	NULL

MacLennan	NULL
ICM	NULL
:	NULL
Germinal	NULL
centers	NULL
Annu	NULL
Rev	NULL
Immunol	NULL
12:117	NULL
,	NULL
1994	NULL
35	NULL
.	NULL

Klein	NULL
G	NULL
:	NULL
Epstein-Barr	NULL
virus	NULL
strategy	NULL
in	NULL
normal	NULL
and	NULL
neoplastic	NULL
B	NULL
cells	NULL
.	NULL

Cell	NULL
77:791	NULL
,	NULL
1994	NULL
36	NULL
.	NULL

Hammarskjold	NULL
ML	NULL
,	NULL
Simurda	NULL
MC	NULL
:	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
transactivates	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
through	NULL
induction	NULL
of	NULL
NF-kappa	NULL
B	NULL
activity	NULL
.	NULL

J	NULL
Virol	NULL
66:6496	NULL
,	NULL
1992	NULL
37	NULL
.	NULL

Laherty	NULL
CD	NULL
,	NULL
Hu	NULL
HM	NULL
,	NULL
Opipari	NULL
AW	NULL
,	NULL
Wang	NULL
F	NULL
,	NULL
Dixit	NULL
VM	NULL
:	NULL
The	NULL
Epstein-Barr	NULL
virus	NULL
LMP1	NULL
gene	NULL
product	NULL
induces	NULL
A20	NULL
zinc	NULL
finger	NULL
protein	NULL
expression	NULL
by	NULL
activating	NULL
nuclear	NULL
factor	NULL
kappa	NULL
B.	NULL
J	NULL
Biol	NULL
Chem	NULL
267:24157	NULL
,	NULL
1992	NULL
38	NULL
.	NULL

Mosialos	NULL
G	NULL
,	NULL
Birkenbach	NULL
M	NULL
,	NULL
Yalamanchili	NULL
R	NULL
,	NULL
VanArsdale	NULL
T	NULL
,	NULL
Ware	NULL
C	NULL
,	NULL
Kieff	NULL
E	NULL
:	NULL
The	NULL
Epstein-Barr	NULL
virus	NULL
transforming	NULL
protein	NULL
LMP	NULL
I	NULL
ALLMAN	NULL
ET	NULL
AL	NULL
engages	NULL
signaling	NULL
proteins	NULL
for	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
family	NULL
.	NULL

Cell	NULL
80:389	NULL
,	NULL
1995	NULL
39	NULL
.	NULL

Henkel	NULL
T	NULL
,	NULL
Ling	NULL
PD	NULL
,	NULL
Hayward	NULL
SD	NULL
,	NULL
Peterson	NULL
MG	NULL
:	NULL
Mediation	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
EBNA2	NULL
transactivation	NULL
by	NULL
recombination	NULL
signal-binding	NULL
protein	NULL
J	NULL
kappa	NULL
.	NULL

Science	NULL
265:92	NULL
,	NULL
1994	NULL
40	NULL
.	NULL

Waltzer	NULL
L	NULL
,	NULL
Logeat	NULL
F	NULL
,	NULL
Brou	NULL
C	NULL
,	NULL
Israel	NULL
A	NULL
,	NULL
Sergeant	NULL
A	NULL
,	NULL
Manet	NULL
E	NULL
:	NULL
The	NULL
human	NULL
J	NULL
kappa	NULL
recombination	NULL
signal	NULL
sequence	NULL
binding	NULL
protein	NULL
(	NULL
RBP-J	NULL
kappa	NULL
)	NULL
targets	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
EBNAZ	NULL
protein	NULL
to	NULL
its	NULL
DNA	NULL
responsive	NULL
elements	NULL
.	NULL

EMBO	NULL
J	NULL
13:5633	NULL
,	NULL
1994	NULL
41	NULL
.	NULL

Yao	NULL
XR	NULL
,	NULL
Scott	NULL
DW	NULL
:	NULL
Inhibition	NULL
of	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
by	NULL
herbimycin	NULL
A	NULL
prevents	NULL
anti-mu	NULL
but	NULL
not	NULL
LPS-mediated	NULL
cell	NULL
cycle	NULL
progression	NULL
and	NULL
differentiation	NULL
of	NULL
splenic	NULL
B	NULL
lymphocytes	NULL
.	NULL

Cell	NULL
Immunol	NULL
149:364	NULL
,	NULL
1993	NULL
42	NULL
.	NULL

Liu	NULL
JL	NULL
,	NULL
Chiles	NULL
TC	NULL
,	NULL
Sen	NULL
RJ	NULL
,	NULL
Rothstein	NULL
TL	NULL
:	NULL
Inducible	NULL
nuclear	NULL
expression	NULL
of	NULL
NF-kappa	NULL
B	NULL
in	NULL
primary	NULL
B	NULL
cells	NULL
stimulated	NULL
through	NULL
the	NULL
surface	NULL
Ig	NULL
receptor	NULL
.	NULL

J	NULL
Immunol	NULL
146:1685	NULL
,	NULL
1991	NULL
43	NULL
.	NULL

Sen	NULL
R	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Inducibility	NULL
of	NULL
kappa	NULL
immunoglobulin	NULL
enhancer-binding	NULL
protein	NULL
Nf-kappa	NULL
B	NULL
by	NULL
a	NULL
posttranslational	NULL
mecha-nism	NULL
.	NULL

Cell	NULL
47:921	NULL
,	NULL
1986	NULL
44	NULL
.	NULL

Ledbetter	NULL
JA	NULL
,	NULL
Grosmaire	NULL
LS	NULL
,	NULL
Hollenbaugh	NULL
D	NULL
,	NULL
Aruffo	NULL
A	NULL
,	NULL
Nadler	NULL
SG	NULL
:	NULL
Agonistic	NULL
and	NULL
antagonistic	NULL
properties	NULL
of	NULL
CD40	NULL
mAb	NULL
G28-5	NULL
are	NULL
dependent	NULL
on	NULL
binding	NULL
valency	NULL
.	NULL

Circ	NULL
Shock	NULL
44:67	NULL
,	NULL
1994	NULL
45	NULL
.	NULL

Francis	NULL
DA	NULL
,	NULL
Karras	NULL
JG	NULL
,	NULL
Ke	NULL
XY	NULL
,	NULL
Sen	NULL
R	NULL
,	NULL
Rothstein	NULL
TL	NULL
:	NULL
Induction	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
NF-kappa	NULL
B	NULL
,	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
during	NULL
B	NULL
cell	NULL
stimulation	NULL
through	NULL
the	NULL
CD40	NULL
receptor	NULL
.	NULL

Int	NULL
Immunol	NULL
7:151	NULL
,	NULL
1995	NULL
46	NULL
.	NULL

Berberich	NULL
I	NULL
,	NULL
Shu	NULL
GL	NULL
,	NULL
Clark	NULL
EA	NULL
:	NULL
Cross-linking	NULL
CD40	NULL
on	NULL
B	NULL
cells	NULL
rapidly	NULL
activates	NULL
nuclear	NULL
factor-kappa	NULL
B.	NULL
J	NULL
Immunol	NULL
153:4357	NULL
,	NULL
1994	NULL
47	NULL
.	NULL

Cheng	NULL
G	NULL
,	NULL
Cleary	NULL
AM	NULL
,	NULL
Ye	NULL
ZS	NULL
,	NULL
Hong	NULL
DI	NULL
,	NULL
Lederman	NULL
S	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Involvement	NULL
of	NULL
CRAFI	NULL
,	NULL
a	NULL
relative	NULL
of	NULL
TRAF	NULL
,	NULL
in	NULL
CD40	NULL
signaling	NULL
.	NULL

Science	NULL
267:1494	NULL
,	NULL
1995	NULL
48	NULL
.	NULL

Hu	NULL
HM	NULL
,	NULL
O'Rourke	NULL
K	NULL
,	NULL
Boguski	NULL
MS	NULL
,	NULL
Dixit	NULL
VM	NULL
:	NULL
A	NULL
novel	NULL
RING	NULL
finger	NULL
protein	NULL
interacts	NULL
with	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
CD40	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
269:30069	NULL
,	NULL
1994	NULL
49	NULL
.	NULL

Han	NULL
S	NULL
,	NULL
Hathcock	NULL
K	NULL
,	NULL
Zheng	NULL
B	NULL
,	NULL
Kepler	NULL
TB	NULL
,	NULL
Hodes	NULL
R	NULL
,	NULL
Kelsoe	NULL
G	NULL
:	NULL
Cellular	NULL
interaction	NULL
in	NULL
germinal	NULL
centers	NULL
.	NULL

Roles	NULL
of	NULL
CD40	NULL
ligand	NULL
and	NULL
B7-2	NULL
in	NULL
established	NULL
germinal	NULL
centers	NULL
.	NULL

J	NULL
Immunol	NULL
155:556	NULL
,	NULL
1995	NULL
50	NULL
.	NULL

Shokat	NULL
KM	NULL
,	NULL
Goodnow	NULL
CC	NULL
:	NULL
Antigen-induced	NULL
B-cell	NULL
elimination	NULL
during	NULL
germinal-centre	NULL
immune	NULL
responses	NULL
.	NULL

Nature	NULL
375:334	NULL
,	NULL
1995	NULL
51	NULL
.	NULL

Pulendran	NULL
B	NULL
,	NULL
Kannourakis	NULL
G	NULL
,	NULL
Nouri	NULL
S	NULL
,	NULL
Smith	NULL
KG	NULL
,	NULL
Nossal	NULL
GJ	NULL
:	NULL
Soluble	NULL
antigen	NULL
can	NULL
cause	NULL
enhanced	NULL
apoptosis	NULL
of	NULL
germinal-centre	NULL
B	NULL
cells	NULL
.	NULL

Nature	NULL
375:331	NULL
,	NULL
1995	NULL
52	NULL
.	NULL

Galibert	NULL
L	NULL
,	NULL
van	NULL
Dooren	NULL
J	NULL
,	NULL
Durand	NULL
I	NULL
,	NULL
Rousset	NULL
F	NULL
,	NULL
Jefferis	NULL
R	NULL
,	NULL
Banchereau	NULL
J	NULL
,	NULL
Lebecque	NULL
S	NULL
:	NULL
Anti-CD40	NULL
plus	NULL
interleukin-4-activated	NULL
human	NULL
naive	NULL
B	NULL
cell	NULL
lines	NULL
express	NULL
unmutated	NULL
immunoglobulin	NULL
genes	NULL
with	NULL
intraclonal	NULL
heavy	NULL
chain	NULL
isotype	NULL
variability	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
25:733	NULL
,	NULL
1995	NULL
53	NULL
.	NULL

Klausner	NULL
RD	NULL
,	NULL
Harford	NULL
JB	NULL
:	NULL
Cis-trans	NULL
models	NULL
for	NULL
post-transcrip-tional	NULL
gene	NULL
regulation	NULL
.	NULL

Science	NULL
246:870	NULL
,	NULL
1989	NULL
54	NULL
.	NULL

Brown	NULL
K	NULL
,	NULL
Gerstberger	NULL
S	NULL
,	NULL
Carlson	NULL
L	NULL
,	NULL
Franzoso	NULL
G	NULL
,	NULL
Siebenlist	NULL
U	NULL
:	NULL
Control	NULL
of	NULL
I	NULL
kappa	NULL
B-alpha	NULL
proteolysis	NULL
by	NULL
site-specific	NULL
,	NULL
signal-induced	NULL
phosphorylation	NULL
.	NULL

Science	NULL
267:1485	NULL
,	NULL
1995	NULL
55	NULL
.	NULL

Lin	NULL
WC	NULL
,	NULL
Desiderio	NULL
S	NULL
:	NULL
Regulation	NULL
of	NULL
V	NULL
(	NULL
D	NULL
)	NULL
J	NULL
recombination	NULL
activator	NULL
protein	NULL
RAG-2	NULL
by	NULL
phosphorylation	NULL
.	NULL

Science	NULL
260:953	NULL
,	NULL
1993	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blO	NULL
0d	NULL
1996	NULL
87	NULL
:	NULL
5257-5268	NULL
BCL-6	NULL
expression	NULL
during	NULL
B-cell	NULL
activation	NULL
4	NULL
_	NULL
5	NULL
,	NULL
'	NULL
_	NULL
>	NULL
,	NULL
#	NULL
04	NULL
;	NULL
@	NULL
``	NULL
20	NULL
D	NULL
Allman	NULL
,	NULL
A	NULL
Jain	NULL
,	NULL
A	NULL
Dent	NULL
,	NULL
RR	NULL
Maile	NULL
,	NULL
T	NULL
Selvaggi	NULL
,	NULL
MR	NULL
Kehry	NULL
and	NULL
LM	NULL
Staudt	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/87/12/5257.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

